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ABSTRACT

The presently-disclosed subject matter relates to an artificial
RNA nanostructure molecule and method to treat brain
tumor in a subject. More particularly, the presently disclosed
subject matter relates to a RNA nanostructure containing a
multiple branched RNA nanoparticle, a brain tumor targeting module, and an effective amount of a therapeutic agent.
Further, the presently disclosed subject matter relates to a
method of using the RNA nano structure composition to treat
brain tumor in a subject having or at risk of having brain
tumor.
27 Claims, 12 Drawing Sheets
Specification includes a Sequence Listing.

US 10,584,144 B2
Page 2
(56)

References Cited

OTHER PUBLICATIONS
Elbashir, Sayda M., et al. "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells." nature 411.
6836 (2001): 494.
Garzon, R. et al., Annu. Rev. Med. 2009, 60, 167-179.
Grapp, M.; Just, I. A.; Linnankivi, T.; Wolf, P.; Lucke, T.; Hausler,
M.; Gartner, J.; Steinfeld, R. Molecular Characterization of Folate
Receptor 1 Mutations Delineates Cerebral Folate Transport Deficiency.
Brain 2012, 135, 2022-2031.
Griffiths-Jones et al. (2006) Nucl. Acids Res. 34:Dl40-Dl44.
Guo, P. The Emerging Field ofRNANanotechnology. Nat. Nanotechnol
2010, 5, 833-842.
Guo, P.; Haque, F.; Hallahan, B.; Reif, R.; Li, H. Uniqueness,
Advantages, Challenges, Solutions, and Perspectives in Therapeutics Applying RNA Nanotechnology. Nucleic Acid Ther. 2012, 22,
226-245.
Guo, P.; Zhang, C.; Chen, C.; Garver, K.; Trottier, M. Inter-RNA
Interaction of Phage Phi29 Prna to Form a Hexameric Complex for
Viral DNA Transportation. Mo!. Cell 1998, 2, 149-155.
Haque, F.; Shu, D.; Shu, Y.; Shlyakhtenko, L. S.; Rychahou, P. G.;
Evers, B. M.; Guo, P. Ultrastable Synergistic Tetravalent RNA
Nanoparticles for Targeting to Cancers. Nano Today 2012, 7,
245-257.
Jasinski, D. L.; Khisamutdinov, E. F.; Lyubchenko, Y. L; Guo, P.
Physicochemically Tunable Polyfunctionalized RNA Square Architecture With Fluorogenic and Ribozymatic Properties. ACS Nano
2014, 8, 7620-7629.
Khisamutdinov, E. F.; Jasinski, D. L.; Guo, P. RNA as a BoilingResistant Anionic Polymer Material to Build Robust Structures
With Defined Shape and Stoichiometry. ACS Nano 2014.
Khisamutdinov, E. F.; Li, H.; Jasinski, D. L.; Chen, J.; Fu, J.; Guo,
P. Enhancing Immunomodulation on Innate Immunity by Shape
Transition Among RNA Triangle, Square and Pentagon Nanovehicles.
Nucleic Acids Res. 2014, 42, 9996-10004.
Lesniak, M. S.; Brem, H. Targeted Therapy for Brain Tumours. Nat.
Rev. Drug Discov. 2004, 3, 499-508.
Li, J.; Zhu, S.; Kozono, D.; Ng, K.; Futalan, D.; Shen, Y.; Akers, J.
C.; Steed, T.; Kushwaha, D.; Schlabach, M. et al. Genome-Wide
Shrna Screen Revealed Integrated Mitogenic Signaling Between
Dopamine Receptor D2 (DRD2) and Epidermal Growth Factor
Receptor (EGFR) in Glioblastoma. Oncotarget 2014, 5, 882-893.
Lorio, M. V., et al., Cancer Res 2005, 65, 7065-7070.
Mao, P.; Joshi, K.; Li, J.; Kim, S. H.; Li, P.; Santana-Santos, L.;
Luthra, S.; Chandran, U. R.; Benos, P. V.; Smith, L.; et al. Mesenchymal
Glioma Stem Cells are Maintained by Activated Glycolytic Metabolism Involving Aldehyde Dehydrogenase 1A3. Proc. Natl. Acad.
Sci. U.S.A 2013, ll0, 8644-8649.
Peruzzi, P.; Bronisz, A.; Nowicki, M. O.; Wang, Y.; Ogawa, D.;
Price, R.; Nakano, I.; Kwon, C. H.; Hayes, J.; Lawler, S. E. et al.

Microrna-128 Coordinately Targets Polycomb Repressor Complexes in Glioma Stem Cells. Neuro Oncol. 2013, 15, 1212-1224.
Quintavalle, C.; Donnarununa, E; Iaboni, M.; Roscigno, G.; Garofalo,
M.; Romano, G.; Fiore, D.; De Marinis, P.; Croce, C. M.; Condorelli,
G. Effect of Mir-21 and Mir-30b/C on TRAIL-Induced Apoptosis in
Glioma Cells. Oncogene 2013, 32, 4001-4008.
Quintavalle, C.; Garofalo, M.; Zanca, C.; Romano, G.; Iaboni, M.;
Del Basso De Caro, M.; Martinez-Montero, J. C.; Incoronato, M.;
Nuovo, G.; Croce, C. M. et al. Mir-221/222 Overexpession in
Human Glioblastoma Increases Invasiveness by Targeting the Protein Phosphate Ptpmu. Oncogene 2012, 31, 858-868.
Rush, D. Periconceptional Folate and Neural Tube Defect. Am. J.
Clin. Nutr. 1994, 59, 5llS-515S; Discussion 515S-516S.
Shu, D.; Khisamutdinov, E. F.; Zhang, L.; Guo, P. Programmable
Folding of Fusion RNA In Vivo and In Vitro Driven by Prna 3WJ
Motif of Phi29 DNA Packaging Motor. Nucleic Acids Res. 2014,
42, El0.
Shu, D.; Moll, W. D.; Deng, Z.; Mao, C.; Guo, P. Bottom-Up
Assembly of RN A Arrays and Superstructures as Potential Parts in
Nanotechnology. Nano Lett. 2004, 4, 1717-1723.
Shu, Dan, et al. "Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of
therapeutics." Nature nanotechnology 6.10 (20ll): 658.
Shu, Y.; Hague, F.; Shu, D.; Li, W.; Zhu, Z.; Koth, M.; Lyubchenko,
Y.; Guo, P. Fabrication of 14 Different RNA Nanoparticles for
Specific Tumor Targeting Without Accumulation in Normal Organs.
RNA 2013, 19, 767-777.
Shu, Yi, et al. "Fabrication of pRNA nanoparticles to deliver
therapeutic RNAs and bioactive compounds into tumor cells."
Nature protocols 8.9 (2013): 1635.
Shu, Yi, et al. "Stable RNA nanoparticles as potential new generation drugs for cancer therapy." Advanced drug delivery reviews 66
(2014): 74-89.
Steinfeld, R.; Grapp, M.; Kraetzner, R.; Dreha-Kulaczewski, S.;
Helms, G.; Dechent, P.; Wevers, R.; Grosso, S.; Gartner, J. Folate
Receptor Alpha Defect Causes Cerebral Folate Transport Deficiency: A Treatable Neurodegenerative Disorder Associated With
Disturbed Myelin Metabolism. Am. J. Hum. Genet. 2009, 85,
354-363.
Suh S. S.; Yoo, J. Y.; Nuovo, G. J.; Jeon, Y. J.; Kim, S.; Lee, T. J.;
Kim, T.; Bakacs, A.; Alder, H.; Kaur, B. et al. Micrornas/TP53
Feedback Circuitry in Glioblastoma Multiforme. Proc. Natl. Acad.
Sci. U.S.A 2012, 109, 5316-5321.
Tae Jin Lee, et al. (2015) Oncotarget, vol. 6, No. 17, 14766-14776.
Weitman, Steven D., et al. "Distribution of the folate receptor GP38
in normal and malignant cell lines and tissues." Cancer research
52.12 (1992): 3396-3401.
Yoo, J. Y.; Pradarelli, J.; Haseley, A.; Wojton, J.; Kaka, A.; Bratasz,
A.; Alvarez-Breckenridge, C. A.; Yu, J. G.; Powell, K.; Mazar, A. P.
et al. Copper Chelation Enhances Antitumor Efficacy and Systemic
Delivery of Oncolytic HSY. Clin. Cancer Res. 2012, 18,
4931-4941.

U.S. Patent

A.

Mar. 10, 2020

B. AFM

FA-Alexa647-pRNA-3WJ-si(Luc)
3;-.yj

10nm

lucifaas~ .;fRNA

+

3'

(5!-11~<;1

IJ

'

5' UUGCCAUG GUI\UG UGGG···CUUACGCUGAGUACUUCGf,_u

I I; I I I; I I I I; i I; 11

3' :!~::,:~GGUAI

i:AC-ACC~'

U•GU

U

I l!i ! ; I! I;!! I;!; I I I

,_:?'-' - :_:,:;,; (;,>.,:; ,.:<·A,'.'.i:'.: ,,. ,,:: :_;

5'

5

3'

A--U
A--IJ bs~w+

C1wJ+ ..4~~~¾:Z-

US 10,584,144 B2

Sheet 1 of 12

r.::.

C--G
U--A
A--U
G·~-c

o--c

5'

dt!:...

0
3·

10

80

-

.,

60

.0

8

C)

..-1

~
QI

·o
:-ioonm

D. Zeta potential

C.DLS

-...

200

~

...

6

V

4

VI

C
::1
0

40

E
::s

...
{?.

z

iv
20

2

0

0

0

15

30

·SO

45

·25

0

25

Zeta potential (mV)

Size (nm}

FIG. I

50

U.S. Patent

A

Mar. 10, 2020

DA?l

B

.,,

0.0±0%

""
Q,

:;; j

~~
"' <(
,.s!Z

< a:
Q.

r!.

tJ
,::
::,
0

u

3

"'<:t"' "'<(.

40.3 ±3.7%

~z

-<( a:
0.

.,

...i ~to
<(

<!>

z t

,-.' ...
i!
"' .

IZ ":"

I'-

i~

"'«t
-z
-r: ~

~~

.s! ~

.,,< ...

"f .,

......l:+
<(

C

US 10,584,144 B2

Sheet 2 of 12

■
■
■
D

C
PBS

FA-Alexa647pRNA-3WJ

_;~. ~'";

Alexa647-

_____ ::c

p:::: 0.019

pRNA-~~"JJ

c2
:E
.....·r..... .

···········.1..····

PBS
{n=4}

FIG.2

Alexa647pRNA-3Wl

FA•Alexa647•
pRNA-3WJ

(n°'4)

{n,,4}

U.S. Patent

Mar. 10, 2020

B

A

~g
2:

1

J

a;

II

i

u E 0,5

<fl

[:'

w

"'

~'.2:
C
·u o

-O-FA-pRNA-3WJ-si(Scrm)

~

.3

- - - FA-pRNA-3WJ-si(Luc)

> 2

·s
:o
·;::;

"'<lJ

---0--- FA-pRNA-3WJ-si(Scrm)

~

0
0

>--0

+-'

3

'O
rl

Q. C
<fl

US 10,584,144 B2

Sheet 3 of 12

....,, FA-pRNA-3WJ-si(luc)

0

/

,,

tiro

·/

.....,t>

a;
Vl

[:'

,,

1

<lJ

~

u

________,(/

::,
_,

0

+-'

~/'

:~

,,,

/

h
't
II

0

0

~

0
0

50

100

200

5

400

7

9

11

13

Days of post tumor implantation

RNA nanopartides [nM]

C

D

2

E

p:0.468

0

2
p,, 0.015

0
FA-·pRNA--3WJ-si(Scrm)

FA--pRNA-3WJ-si(luc)

FIG.3

FA-pRNA-3WJ-si{Scrm) FA-pRNA-3WJ-si{Luc)

U.S. Patent

Mar. 10, 2020

A
PBS

C044-FITC

~--~-----~~---~-----~

,/;

0,2.t0.3%

US 10,584,144 B2

Sheet 4 of 12

().4±0.7%

Alexa647-pRNA-3WJ
FA-Alexa647-pRNA-3WJ
+ CD44-FITC
+ C044-FITC
... ---·············· ······················.········~--~-----~

12,7±0.4%

33.2±0.8%

i
:l~-~

-:i

::
li

"'j

: <
l ·i

l:; !

~ ...............~,; ..•r ..,..,.._.._~1r..

"i

li
~•••r(M1.. •~•..,•~!~~~

4..

•~•'\•~•rr.'\~ .. •r• • •r~~~r'f......... .._........."f.;.;, • ..,•~~..,.._~'l

!

n-;•-;••"iV-"(n•;-, •,~ ;{•'/' _ -;-;-;--1•:r•••;-;-.-.;•J Nf'••••:,•,-,•,,•.'.>,-:-J••••••,"•".•",-.-.V,'l'"'"'"'O"',•,-,,:,-,q-•••••.••V•,••••
❖

'

CD44-FITC

C

B
PBS

control

Alexa647pRNA-3WJ

fA-Alexa641pRNA-3WJ

Fluorescence {Alexa647)
PllS

Alexa647--

FA-Ale)la647•

control

pRNA-3WJ

pRNA-3WJ
10

..,.,

f

r!>

8

8
::,

hi

,.

5'
e+

::,

:C.

6~
X

.§
4

FIG.4

U.S. Patent

Mar. 10, 2020

Sheet 5 of 12

US 10,584,144 B2

<+···

t

l 1t\

tJ~!ll,L . ..
@fill .i>.:tMfi,ft-·p::lNA·J•'i.l i:lNi"
-

FIG.5

~=A~t-.}~~~~~{>'+l··>~f~N..-,.•J~ii *~:~f~

U.S. Patent

Mar. 10, 2020

Sheet 6 of 12

US 10,584,144 B2

FA•Alexa647•p-RNA•3WJ

FIG.6

U.S. Patent

Mar. 10, 2020

Sheet 7 of 12

US 10,584,144 B2

Merged

DAPI

FIG. 7

FIG.8

U.S. Patent

Mar. 10, 2020

Sheet 8 of 12

US 10,584,144 B2

3WJCor:ij

ui

!is;

Strand 1

31

tU UGCCAUG GUAUGUGGGiAUCCCGC GGCCAUGGCGGCCGGGAG
1111111111

a~ j!AACGGUA.C

~I I 1111111111111 I 1111

I

i
LJ.. Gu

'

A U

I Strand 1
II

I
:

:,:

• 11 11111111111 l

CAU. ACACC~~ !fi-GGGCGCCGGTACCGCCGGCCCTC TCCJd\fI\C.'. 5'
Uu
..i
.;,
Strand 4
(:.nt; .. rniin .. ::::·:i

~····g

Strand 3

!g

5' G-C 3'

.•.•.•:•:•:•:•:•:•:•:•:•:•:❖:❖:❖:❖:❖:❖:❖:::

't-. ,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.

Foh~t:£!
FIG.9A
FA-3WJ-LNA-miR21

None

FIG. 9B

U.S. Patent

Mar. 10, 2020

Sheet 9 of 12

FIG.1O

US 10,584,144 B2

U.S. Patent

Mar. 10, 2020

Sheet 10 of 12

US 10,584,144 B2

FIG.11

B.

A.

p= 0.023

FIG.12

U.S. Patent

Mar. 10, 2020

..................•.•.•.•.•.•.•.•.•.•.•.•.•r·············::::·: ~

Turnor

FIG.13

FA-3WJ

LNAASC

_.;

,.

-;

~

;i

~

"'-· ...•_( ;- ::

~~

~~- ~

::F'.A•.s,~d-,;:..NA•m<R..:. l: :;-A- .H\<._,f•d-.A•.:>t.,

I.

A.

US 10,584,144 B2

Sheet 11 of 12

B.
FA-3V'</,J
LNA-SC

··················· ... ·::::::::::::::::::::::::::::::::·•• .
......,.~::::.3/:#<w:w:::w:w:w:;:w:;:;=:w

FIG.14

Treate~ tumor

U.S. Patent

-~,_>

Mar. 10, 2020

100

ti)'

;:;i
~

_,..,

I:

• p=0.0023

50 •

ii.I

q.....

...
0

.~

C(I

0.

0

0

1-0

US 10,584,144 B2

Sheet 12 of 12

20

30

FIG.15

.,._

FA-3WJ-LNA-SC

,......,

FA•3WJ.LNA--miR21

US 10,584,144 B2
1

2

RNA NANOPARTICLES FOR BRAIN TUMOR
TREATMENT

intermolecular base-pairing via the interaction of two interlocking loops, the pRNA molecules form dimers, trimers,
hexamers, and patterned superstructures [7]. This property
of forming self-assembled nano structure makes pRNA ideal
building blocks for bottom-up assembly. RNA nanotechnology has been rapidly growing as a new generation platform
for biological and medical application (2-3). As nanotechnology rapidly evolves, many attempts have been made to
deliver small interfering RNA (siRNA) using viruses, liposome, lipid, and polymer based nanoparticles (4).
Clearly there remains a need for improved composition
and methods targeting both brain tumor cells and glioblastoma stem cells to treat the primary brain tumor and prevent
tumor recurrence is desired. The presently disclosed subject
matter relates to RNA nanoparticle containing compositions
useful for prophylactic and therapeutic treatment for brain
tumors.

RELATED APPLICATIONS
5

This application is a § 371 National State Application of
PCT/US2016/021447 filed Mar. 9, 2016 which claims the
benefit of U.S. Provisional Patent Application No. 62/130,
459, filed Mar. 9, 2015, the entire disclosures of which are
hereby incorporated by reference in their entirety.

10

GOVERNMENT INTEREST
This invention was made with govermnent support under
CA151648 (P.G.), EB012135 (P.G.), CA152758 (C.M.C.),
CAI 75875 (I.N.), CA163205 (I.N.), P30NS045758 (B.K.),
R01064607
(B.K.),
R01CA150153
(B.K.),
and
P01CA163205 (B.K.) awarded by the National Institutes of
Health. The govermnent has certain rights in the invention.

15

SUMMARY
20

SEQUENCE LISTING
The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is
hereby incorporated by reference in its entirety. Said ASCII
copy, created on Mar. 30, 2018, is named 2935720-7 SL.txt
and is 4,791 bytes in size.

25

TECHNICAL FIELD
30

The presently-disclosed subject matter relates to an artificial RNA nanostructure molecule and method to treat brain
tumor in a subject. More particularly, the presently disclosed
subject matter relates to a RNA nanostructure containing a
multiple branched RNA nanoparticle, a brain tumor targeting module, and an effective amount of a therapeutic agent.
Further, the presently disclosed subject matter relates to a
method of using the RNAnanostructure composition to treat
brain tumor in a subject having or at risk of having brain
tumor.

35

40

INTRODUCTION
The most common primary brain tumors in adults are
glioblastomas, which are also one of the most deadly cancers
(1). For glioblastomas, conventional treatment involves surgical resection followed by radiation and concurrent chemotherapy. Even with this treatment regimen, the median
survival of patients with glioblastoma is less than 15 months.
The poor prognosis is primarily due to tumor recurrence,
which is thought to originate from a subset of cancer stem
cells that survive the primary treatments. Recent studies
suggested that glioblastoma stem cell survived the therapeutic stresses and become more aggressive when they recur,
developing resistance to the primary chemotherapy.
Bacterial virus phi29 DNA packaging RNA (pRNA)
molecule is a crucial component in the phi29 DNA packaging motor and contains two functional domains. The
intermolecular interaction domain is located at the central
region (bases 23-97) and within this domain there are two
loops (right hand loop and left hand loop) which are responsible for the hand-in-hand interaction through the four
complementary base sequences within these two loops. The
other domain is a DNA translocation domain which is
located at the 5'/3' paired ends. The right hand loop (bases
45-48) and the left hand loop (bases 82-85) allow for the
formation of pRNA dimers, trimers and hexamer rings via

45

50
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60
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The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
This Summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
Summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the feature(s) mentioned; likewise, those features can be applied to
other embodiments of the presently-disclosed subject matter, whether listed in this Summary or not. This Summary
does not list or suggest all possible combinations of such
features.
In some embodiments, the presently disclosed subject
matter provides an artificial RNA nanostructure molecule.
The molecule includes a multiple branched RNA junction
motif comprising at least one RNA oligonucleotide, and a
brain tumor targeting module, and the module is coupled to
an RNA junction motif. In some embodiments, the molecule
further includes at least one bioactive agent coupled to the
RNA junction motif. A non-limiting example of the bioactive agent is a a therapeutic agent. In some embodiments, the
RNA oligonucleotide is at least 6 nucleotides in length. In
some embodiments, the RNA oligonucleotide includes at
least one chemical modification at the 2' position. Nonlimiting examples of the chemical modification include
2'Fluoro, 2'Amine, 2'O-Methyl, or a combination thereof.
In some embodiments, the multiple branched RNA
includes a nucleotide sequence 5'-UUG CCA UGU GUA
UGU GGG AUC CCG CGG CCA UGG CGG CCG GGA
G-3' (SEQ ID NO: 6). In some embodiments, the multiple
branched RNA includes a sequence 5' GATAAGCT CTC
CCG GCC GCC ATG GCC GCG GGA T-3' (SEQ ID NO:
7). In some embodiments, the multiple branched RNA
junction motif is a three-branched RNA junction motif. In
some embodiments, the three-branched RNA junction motif
includes a packaging RNA (pRNA) three-way junction
(3WJ) motif. In some embodiments of the present disclosure, the RNA molecules form dimers, trimers, hexamers,
and patterned superstructures.
In some embodiments, the presently disclosed subject
matter provides that a branch of the three-branched RNA
junction motif includes an a3WJ RNA module. In some
embodiments, a branch of the three-branched RNA junction
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motif includes a b3 WJ RNA module. In some embodiments,
a branch of the three-branched RNA junction motif includes
a c3WJ RNA module. In some embodiments, the threebranched RNA junction motif includes an a3WJ RNA
module, a b3WJ RNA module, and a c3WJ RNA module. A
non-limiting example of RNA module include nucleotide
sequences 5'-UUG CCA UGU GUA UGU GGG-3' (SEQ ID
NO: 1), 5'-CCC ACA UAC UUU GUU GAUCC-3' (SEQ ID
NO: 2), and 5'-GGA UCA AUC AUG GCA A-3' (SEQ ID
NO: 3).
In some embodiments, the diameter of the molecule is at
least about 40 nm or less. In some embodiments, the
diameter of the molecule is at least about 30 nm or less. In
some embodiments, the diameter of the molecule is at least
about 15 nm or less.
In some embodiments, the RNA molecule has a zeta
potential ranging from about -50 mV to about 50 mV. In
some embodiments, the molecule has a zeta potential ranging from about -25 my to about 25 mV.
In some embodiments, the presently disclosed subject
matter provides that the brain tumor targeting module in the
artificial RNA nano structure molecule includes a ligand that
binds to at least one brain tumor cell surface marker.
Non-limiting examples of the brain tumor surface marker
includes folate receptor, EGFR, transferrin receptor, and an
RGD. In some embodiments, the ligand includes an aptamer.
In some embodiments, the aptamer binds to EGFR, PDGFR,
folate receptor, or a combination thereof. In some embodiments, In some embodiments, the targeting module is a
folate.
In some embodiments, the presently disclosed subject
matter provides a bioactive agent includes a drug, a fluorescent dye, a chemical, or a combination thereof. In some
embodiments, the bioactive agent includes a siRNA, a
miRNA, an anti-miRNA, a ribozyme RNA, an antisense
RNA, or a combination thereof. In some embodiments, the
bioactive agent is directed to a brain tumor marker. Nonlimiting examples of the bioactive agent include siRNA
sequence and microRNA sequence. In some embodiments,
the microRNA molecule is at least 3 nucleotide in length. In
some embodiments, the bioactive agent is an anti-miRNA
molecule for a miRNA encoding miR-9, miR-l0b, miR-21,
miR-17, or miR-26. In some embodiments, the bioactive
agent is a miRNA molecule for a miRNA encoding let-7a,
miR-l0b, miR-25, miR-34a, miR-124, miR-145, or miR181b. In some embodiments, the miRNA includes miRNA
locked nucleic acid (LNA) molecule. In some embodiments,
the microRNA sequence is an anti-miR-21 sequence. In
some embodiments, non-limiting examples of the miRNA
sequence comprises 5'-GATAAGCT-3', 5'-AGCACTTT-3',
or 5'-ATTTGCAC-3'. In some embodiments, the miRNA
includes an miRNA locked nucleic acid (LNA) molecule. In
some embodiments, the bioactive agent includes a LNA
miRNA molecule 5'-+G+A+T+A+A+G+C+T-3'. In some
embodiments, miRNA LNA molecule includes a sequence
5'-+A+G+C+A+C+T+T+T-3'. In some embodiments,
miRNALNAmolecule includes a sequence 5'-+A+T+T+T+
G+C+A+C-3'.
In some embodiments, the microRNA is a locked nucleic
acid (LNA) sequence. In some embodiments, the microRNA
is a LNA-miR21 sequence 5'-+G+A+T+A+A+G+C+T-3'. In
some embodiments, the siRNA binds to a mRNA sequence
of a gene that promotes tumorigenesis, angiogenesis, cell
proliferation, or a combination thereof, in the brain or spinal
cord. In some embodiments, the siRNA binds to a mRNA
molecule that encodes a protein including pro-tumorigenic
pathway proteins, pro-angiogenesis pathway proteins, pro-

cell proliferation pathway proteins, anti-apoptotic pathway
proteins, or a combination thereof. In further embodiments,
the mRNA molecule encodes a protein including but not
limited to VEGF pathway proteins, EGFR pathway proteins,
MGMT pathway proteins, Rafi pathway proteins, MMP
pathway proteins, mTOR pathway proteins, TGF~ pathway
proteins, or Cox-2 pathway proteins, or a combination
thereof. In some embodiments, non-limiting examples of
protein include VEGF, EGFR, POK, AKT, AGT, RAF, RAS,
MAPK, ERK, MGMT, MMP-2, MMP-9, PDGF, PDGFR,
IGF-I, HGF, mTOR, Cox-2 and TGF~l. In some embodiments, the siRNa binds to a mRNA molecule that encodes
RAS, cMET, HER2, MDM2, PIK3CA, AKT, CDK4, or a
combination thereof.
Further provided, in some embodiments of the presently
disclosed subject matter, is a nucleic acid composition. The
composition includes a therapeutically effective amount of
the artificial RNA nanostructure molecule as disclosed
above. In some embodiments, the composition includes a
pharmaceutically acceptable carrier.
Still further, the presently disclosed subject matter, in
some embodiments, provides a nanoparticle delivery system. The delivery system includes the artificial RNA nanostructure molecule as disclosed above. In some embodiments, the nanoparticle delivery system further includes a
pharmaceutically acceptable carrier.
In another aspect, the presently disclosed subject matter
provides, in some embodiments, a method of treating a brain
tumor in a subject having or at risk of developing a brain
tumor. The method includes administering to the subject a
therapeutically effective amount of a composition comprising an artificial RNA nanostructure molecule as disclosed
herein. In some embodiments, the composition includes a
pharmaceutically acceptable carrier. In some embodiments,
the subject is a mammal or a non-mammal vertebrate. In
some embodiments, the subject is a human. In some embodiments, the brain tumor is glioblastoma.
Further, in some embodiments, the present disclosure
provides a method of preventing brain tumor recurrence a
subject having or at risk of having brain tumor recurrence.
The method includes administering to the subject a therapeutically effective amount of a composition comprising an
artificial RNA nanostructure molecule as disclosed herein.
In some embodiments, the composition includes a pharmaceutically acceptable carrier. In some embodiments, the
subject is a mammal or a non-mammal vertebrate. In some
embodiments, the subject is a human. In some embodiments,
the brain tumor is glioblastoma.

5

10

15

20

25

30

35

40

45

50

55

60

65

BRIEF DESCRIPTION OF THE DRAWINGS
The features of the presently disclosed subject matter are
set forth with particularity in the appended claims. A better
understanding of the features and advantages of the presently disclosed subject matter will be obtained by reference
to the following detailed description that sets forth illustrative embodiments, in which the principles of the subject
matter are used, and the accompanying drawings of which.
The drawings were originally published in color, incorporated by reference in their entireties (Tae Jin Lee, et al.
(2015) Oncotarget, Vol. 6, No. 17, 14766-14776). The black
and white drawings of the instant application correspond to
the color ones published.
FIGS. lA-lD are diagrams and images illustrating construction and characterization of multi-functional pRNA3WJ RNP for glioblastoma cell targeting. A, Construction
map of trivalent FA-Alexa647-pRNA-3WJ-si(Luc) RNP
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harboring three functionalities to form: Folate (FA) as a
targeting ligand; Alexa647 as an imaging module; and
luciferase siRNA for gene silencing. FIG. lA discloses SEQ
ID NOS 19, 3, 2 and 5, respectively, in order of appearance.
B, Atomic force microscopy (AFM) image showing threebranched triangular structure of self-assembled trivalent
FA-pRNA-3WJ-si(Luc) RNP. C, Dynamic light scattering
(DLS) data showing the size of FA-pRNA-3WJ-si(Luc)
RNP. D, Zeta potential ofFA-pRNA-3WJ-si(Luc) RNP. The
data in C and D were obtained from three independent
experiments.
FIGS. 2A-2D are graphs and images showing FA-mediated human glioblastoma cell targeting by FA-Alexa647pRNA-3WJ RNP in vitro and in vivo. A, Flow cytometry
analysis for FA-dependent human glioblastoma cell
U87EGFRvIII targeting in vitro by FA-Alexa647-pRNA3WJ RNP. Alexa647 signals from U87EGFRvIII cells
treated with 200 nM ofFA-Alexa647-pRNA-3WJ RNP were
compared to control RNP (FA-free Alexa647-pRNA-3WJ
RNP) normalized to PBS control. Percentage of cell populations were analyzed by student t-test (p<0.001, n=4). B,
Immunofluorescence confocal microscopy for FA-dependent human glioblastoma cell U87EGFRvIII targeting in
vitro by FA-Alexa647-pRNA-3WJ RNP (middle) in comparison to control RNP (FA-free Alexa647-pRNA-3WJ)
(top) or 1 mM free folate pre-treated cells in culture media
(bottom). Pseudocolor was used for nucleus (blue), cytoskeleton (green) and Alexa647 (red). C, U87EGFRvIIIinduced brain tumors in mice targeted by FA-Alexa647pRNA-3WJ RNP. Tumors were determined by MRI (yellow
arrows in top panel) and visualized by fluorescence in vivo
imaging (bottom panel) after tail vein injection of FA or
FA-freeAlexa647-pRNA-3WJ RNP. Representative images
from each group of 4 were displayed. D, ANOVA analysis
on fluorescence intensity of Alexa647 normalized by tumor
volume (mm3 ), p=0.019 (n=4).
FIGS. 3A-3E are graphs and images showing gene silencing effect of FA-pRNA-3WJ-si(Luc) RNP in human glioblastoma cells and derived tumor. A, A wide range (up to 400
nM) of FA-pRNA-3WJ-si(Luc) (closed circles) or
FA-pRNA-3WJ-si(Scrm) (negative control, open circles)
RNPs were incubated with U87EGFRvIII-Luc cells in vitro
(n-=4). The change of luciferase activity was monitored
versus the concentration of the RNPs. B, Luciferase gene
silencing effect ofFA-pRNA-3WJ-si(Luc) in vivo after total
of three injections. Luciferase activity change by FA-pRNA3WJ-si(Luc) (closed circles) or FA-pRNA-3WJ-si(Scrm)
(open circles) were compared by mean bioluminescence
intensity (n=5), p=0.007. C, Representative in vivo MRI
images for tumor volume and bioluminescence intensity for
luciferase activity from both FA-pRNA-3WJ-siRNA(Luc)
or FA-pRNA-3WJ-si(Scrm) after three injections. D, Tumor
volumes calculated from MRI compared to scrambled control group at day 13 post-xenograft, p=0.468 (n=5). E, Mean
fluorescence intensity divided by tumor volume (mm3 ) was
used to normalize the variation among the tested mice,
p=0.015 (n=5). All error bars indicate s.e.m., and student
t-test was used for statistical analysis.
FIGS. 4A-4C are graphs and images showing FA-mediated targeting of human glioblastoma patient-derived stem
cell and derived brain tumor by FA-Alexa647-pRNA-3WJ
RNPs in animal trials and biodistribution study. A. Flow
cytometry analysis for in vitro targeting of human glioblastoma patient-derived stem cell, 1123, by FA-Alexa647pRNA-3WJ or Alexa647-pRNA-3WJ RNP co-treated with
CD44-FITC antibody. PBS and CD44-FITC treated cells
were used as gating controls. B, Mouse brain tumor derived

from 1123 cells was evaluated by MRI for tumor size
determination (top). After systemic administration ofFA-Alexa647-pRNA-3WJ RNP, FA-dependent targeting was visualized by fluorescence in vivo imaging in comparison to
FA-free Alexa647-pRNA-3WJ RNP. C, Biodistribution profile of FA-Alexa647-pRNA-3WJ RNP was obtained by
imaging fluorescence against Alexa647 from major internal
organs collected together with brain.
FIG. 5 is graphs illustrating flow cytometry analysis for
FA-mediated human glioblastoma cell targeting by FA-Alexa647-pRNA-3WJ RNP in vitro. Human glioblastoma cells
U87EGFRvIII were pre-treated with 1 mM free folate in
culture media for 1 hr before incubation with FA-Alexa647pRNA-3WJ RNP containing medium. Events as a function
of Alexa647 signal intensity detected from U87EGFRvIII
cells treated with 200 nM ofFA-Alexa647-pRNA-3WJ RNP
were compared to control RNP (FA-free Alexa647-pRNA3WJ RNP). The figure is representative of three experiments.
FIG. 6 contains images showing FA-mediated human
glioblastoma cell T98G in vitro targeting by FA-Alexa647pRNA-3WJ RNPs. Glioblastoma multiforme (GBM) cell
line, T98G, was treated with 200 nM of FA-Alexa647pRNA-3WJ or Alexa647-pRNA-3WJ for 1 hr, followed by
fluorescence confocal microscopy. Pseudocolor was used for
nuclear (blue), cytoskeleton (green) and Alexa647 (red).
FIG. 7 includes images showing confocal fluorescence
imaging of frozen sectioned brain tumor derived from
human glioblastoma patient-derived stem cell 1123 demonstrating the distribution and accumulation of FA-Alexa647pRNA-3WJ RNP in brain tumor cells (yellow arrows).
Pseudocolor was used for nuclear (blue), and Alexa647
(red).
FIG. 8 includes images showing human glioblastoma
patient-derived stem cell 1123-derived mouse brain tumor
targeting by FA-Alexa647-pRNA-3WJ RNPs with RNA
dose-dependent (100>20 µg/mouse) manner. The fluorescence intensity for the tumor-bearing mouse brains were
evaluated at 15 hrs after systemic injection of RNPs.
FIG. 9A is a diagram illustrating the construction map of
trivalent FA-3WJ-LNA-miR21. FIG. 9A discloses SEQ ID
NOS 6, 3, 2 and 7, respectively, in order of appearance. FIG.
9B includes graphs illustrating FA-mediated in vitro human
glioblastoma cell targeting determined by flow cytometry.
FIG. 10 includes images showing FR-dependent human
glioblastoma cell targeting visualized by confocal fluorescent microscopy.
FIG. 11 includes images showing confocal fluorescent
microscopy analysis visualizes human glioblastoma cell
specific distribution.
FIG. 12 includes graphs and images showing anti-tumor
effect of systemically delivered FA-3WJ-LNA-miR21 RNP
in human glioblastoma cells derived tumor in vivo.
FIG. 13 is a graph illustrating knock-down of endogenous
miR-21 in mouse tumor by systemically delivered FA-3WJLNA-miR21.
FIGS. 14Aand 14B are graphs and images showing down
regulation of miR-21 by systemically delivered FA-3WJLNA-miR21 induced apoptotic pathway through recovery
of Pten protein expression.
FIG. 15 is a graph showing knock-down of endogenous
miR-21 in mouse tumor by systemically delivered FA-3WJLNA-miR21 improved overall survival of brain tumorbearing mice.

5

10

15

20

25

30

35

40

45

50

55

60

DESCRIPTION OF EXEMPLARY
EMBODIMENTS
65

The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
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Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom.
In certain instances, nucleotides and polypeptides disclosed herein are included in publicly-available databases,
such as GENBANK® and SWISSPROT. Information
including sequences and other information related to such
nucleotides and polypeptides included in such publiclyavailable databases are expressly incorporated by reference.
Unless otherwise indicated or apparent the references to
such publicly-available databases are references to the most
recent version of the database as of the filing date of this
Application.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth to facilitate explanation of the presently-disclosed
subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1%, in some embodiments ±0.5%, and in some embodiments ±0.1 % from the specified amount, as such variations
are appropriate to perform the disclosed method. As used
herein, ranges can be expressed as from "about" one particular value, and/or to "about" another particular value. It is
also understood that there are a number of values disclosed
herein, and that each value is also herein disclosed as
"about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
The presently-disclosed subject matter relates to RNA
nanostructure molecule and method to treat brain tumor in a
subject. More particularly, the presently disclosed subject
matter relates to a molecule containing a multiple branched
RNA junctive motif, a brain tumor targeting module. Fur-

ther, the presently disclosed subject matter relates to a
method of using the RNA nano structure composition to treat
brain tumor in a subject having or at risk of having brain
tumor.
In some embodiments, the presently disclosed subject
matter provides an artificial RNA nanostructure molecule.
The molecule includes a multiple branched RNA junction
motif comprising at least one RNA oligonucleotide, and a
brain tumor targeting module, and the module is coupled to
an RNA junction motif. In some embodiments, the molecule
further includes at least one bioactive agent coupled to the
RNA junction motif. In some embodiments, the RNA oligonucleotide is at least about 6 nucleotides in length.
RNA nanotechnology has recently emerged as an important field due to recent finding of its high thermodynamic
stability, favorable and distinctive in vivo attributes (US
2014/0179758, hereby incorporate by reference in its
entirety). In some embodiments of the present disclosure, as
disclosed in US2014/0179758, the RNA molecules form
dimers, trimers, hexamers, and patterned superstructures.
Further, RNA nanoparticles can be fabricated with precise
control of shape, size and stoichiometry, as demonstrated by
the packaging RNA (pRNA) of the bacteriophage phi29
DNA packaging motor, which forms dimmers, trimers, and
hexamers via hand-in-hand interactions of the interlocking
loops.
In some embodiments, the presently disclosed subject
matter relates to a RNA nanoparticle based composition.
Such nanoparticles is delivered systemically and specifically
target intracranial tumors with minimal toxicity. In some
embodiments, the nanoparticle relates to a pRNA three-way
junction (pRNA-3WJ). The pRNA-3WJ of the bacteriophage phi29 DNA packaging motor can be used to fabricate
a RNA nanoparticle (RNP) with precise control of shape,
size and stoichiometry (4-10). Creation of boiling resistant
RNPs with controllable shapes and defined stoichiometry
has been recently reported (11).
The term "RNA" refers to a molecule comprising at least
one ribonucleotide residue. By "ribonucleotide" is meant a
nucleotide with a hydroxyl group at the 2' position of a
~-D-ribofuranose moiety. The terms encompass double
stranded RNA, single stranded RNA, RNAs with both
double stranded and single stranded regions, isolated RNA
such as partially purified RNA, essentially pure RNA,
synthetic RNA, recombinantly produced RNA, as well as
altered RNA, or analog RNA, that differs from naturally
occurring RNA by the addition, deletion, substitution, and/or
alteration of one or more nucleotides. Such alterations can
include addition of non-nucleotide material, such as to the
end(s) of an siRNA or internally, for example at one or more
nucleotides of the RNA. Nucleotides in the RNA molecules
of the presently disclosed subject matter can also comprise
non-standard nucleotides, such as non-naturally occurring
nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as
analogs or analogs of a naturally occurring RNA.
In some embodiments, the RNA oligonucleotide of the
RNA nanoparticles includes at least one chemical modification at the 2' position. Non-limiting examples of the
chemical modification include 2'Fluoro, 2'Amine, 2'OMethyl, or a combination thereof. In one embodiments, the
pRNA-3WJ nanoparticles with 2'-Fluoro (2'-F) modifications of U and C nucleotides renders the RNPs resistant to
RNase degradation enhancing their in vivo half-life while
retaining authentic functions of the incorporated modules (7,
12, 13). Furthermore, the pRNA-3WJ RNPs were non-toxic,
non-immunogenic, and displayed favorable biodistribution

5

10

15

20

25

30

35

40

45

50

55

60

65

US 10,584,144 B2
9

10

and pharmacokinetic profiles in mice (14). These favorable
characteristics make this novel platform attractive for the
systemic delivery of siRNA to glioblastoma. One promising
ligand for nanoparticle therapy in glioblastoma targeting is
folate, a natural member of the B-vitamin family. Folate is
required for early neuronal development and differentiation
(15). Its transportation across the blood-cerebrospinal fluid
barrier (BCSF) occurs by the choroid plexus (16). The
choroid plexus expresses the largest amount of folate receptor (FR) in a body, while no FR expression is detected in
cerebellum, cerebrum or spinal cord (17,18).
In some embodiments, the multiple branched RNA
includes a nucleotide sequence 5'-UUG CCA UGU GUA
UGU GGG AUC CCG CGG CCA UGG CGG CCG GGA
G-3' (SEQ ID NO: 6). In some embodiments, the multiple
branched RNA includes a sequence 5'-GATAAGCT CTC
CCG GCC GCC ATG GCC GCG GGA T-3' (SEQ ID NO:
7). In some embodiments, the presently disclosed subject
matter provides that a branch of the three-branched RNA
junction motif includes an a3WJ RNA module. In some
embodiments, a branch of the three-branched RNA junction
motif includes a b3 WJ RNA module. In some embodiments,
a branch of the three-branched RNA junction motif includes
a c3WJ RNA module. In some embodiments, the threebranched RNA junction motif includes an a3WJ RNA
module, a b3WJ RNA module, and a c3WJ RNA module. A
non-limiting example of RNA module include nucleotide
sequences 5'-UUG CCA UGU GUA UGU GGG-3' (SEQ ID
NO: 1), 5'-CCC ACA UAC UUU GUU GAUCC-3' (SEQ ID
NO: 2), and 5'-GGA UCA AUC AUG GCA A-3' (SEQ ID
NO: 3).
In some embodiments, the diameter of the molecule is at
least about 40 nm or less. The diameter is at least about 35
nm or less, at least about 30 nm or less, at least about 25 nm
or less, at least 20 nm or less, at least 15 nm or less, at least
10 nm or less, at least 5 nm or less.
In some embodiments, the molecule has zeta potential
ranging from about -150 m V to about 150 m V. The RNA
molecule has a zeta potential ranging from about -140 mV
to about 140 mV, from about -130 mV to about 130 mV,
from about -120 m V to about 120 m V, from about -110 m V
to about 110 mV, from about -100 mV to about 100 mV,
from about -90 to about 90 m V, form about -80 m V to about
80 m V, from about - 70 m V to about 70 m V, from about -60
m V to about 60 m V. In some embodiments, the RNA
molecule has a zeta potential ranging from about -50 m V to
about 50 m V. The molecule has a zeta potential ranging from
about -45 my to about 45 m V, from about -40 m V to about
40 m V, from about -35 m V to about 35 m V, from about -35
mV to about 30 mV, from about -35 mV to about 20 mV,
from about -25 mV to about 15 mV.
In some embodiments, the RNA nanostructure molecule
is substantially stable in pH ranges from about 2 to about 13.
The RNA molecule is substantially stable in pH about 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12 and 13. As used herein, the term
"substantially stable" can refer to physical and/or chemical
stability. As will be recognized by those of ordinary skill in
the art, the term "substantially stable" can refer to stability
of the composition under certain conditions, relative to an
initial composition (i.e., when a particular batch of the
composition is initially prepared). In this regard, as will be
recognized by those of ordinary skill in the art, one manner
in which stability of a particular embodiment of the composition can be determined is as follows: preparing a batch
of the embodiment of the composition, making an initial
assessment of a sample of the composition (control sample),
subjecting a sample of the composition to conditions of

interest (e.g., storage at a particular temperature for a
particular time period) (test sample), making an assessment
of the test sample, and comparing the assessment of the
control sample to the assessment of the test sample. Calculations can be made to determine whether the amounts
present in the test sample are 100%±20, 19, 18, 17, 16, 15,
14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, or 0.1 % of the
amount that is in the control sample.
In some embodiments, the presently disclosed subject
matter provides that the brain tumor targeting module in the
artificial RNA nano structure molecule includes a ligand that
binds to at least one brain tumor cell surface marker. As used
herein, cell surface markers include any cellular component
that may be detected within or on the surface of a cell, or a
macromolecuie bound or aggregated to the surface of the
cell. As such, cell surface markers are not limited to markers
physically on the surface of a cell. For example, cell surface
markers may include, but are not limited to surface antigens,
transmembrane receptors or coreceptors, macromolecules
bound to the surface, such as bound or aggregated proteins
or carbohydrates, internal cellular components, and the like.
Non-limiting examples of the brain tumor surface marker
includes folate receptor, EGFR, transferrin receptor, and an
RGD. In some embodiments, the ligand includes an aptamer.
In some embodiments, the aptamers binds against EGFR,
PDGFR, or folate receptor. In some embodiments, the
targeting module is a folate.
In some embodiments, a brain tumor targeting module is
coupled to the RNA nanoparticle. The targeting module
direct the nanoparticle to the brain tumor cells, to enhance
binding to them, to enhance internalization, to enhance
targeting to cellular enzymes, DNA, RNA, proteins, lipids,
or carbohydrates. Non-limiting examples of the brain tumor
targeting module are antibodies, antibody fragments, polypeptides, cell ligands, aptamers, DNA. RNA, drugs, compounds that enhance targeting the brain tumor cell, and other
groups or materials that enhance binding to brain tumor
cells.
In some embodiments, a brain tumor targeting module
may be an antibody. The antibody may have an ability to
recognize and specifically bind to a target on tumor cells and
tissues. Non-limiting example of the antibody is an antibody
configured to specifically bind a protein selected from but
not limited to EGFR, human epidermal growth factor
(HER), laminin 411, insulin-like growth factor (IGF) and
tumor necrosis factor-alpha (TNF-a).
In some embodiments, a targeting module is an antibody
of a class described as antagonist antibodies, which specifically bind to a brain tumor stem cell marker protein and
interfere with, for example, ligand binding, receptor
dimerization, expression of a brain tumor stem cell marker
protein, and/or downstream signaling of a cancer stem cell
marker protein. Yet in other embodiments, a targeting module is an antibody of a class described as agonist antibodies
which specifically bind to a brain tumor stem cell marker
protein and promote, for example, ligand binding, receptor
dimerization, and/or signaling by a cancer stem cell marker
protein. Yet in further embodiments, a targeting module is an
antibody that does not interfere with or promote the biological activity of a brain tumor stem cell marker protein and
may instead function to inhibit tumor growth by, for
example, antibody internalization and/or recognition by the
immune system.
In some embodiments, the targeting module may include
a lectin or another ligand specific to the transferrin receptor.
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A brain tumor targeting module may further e a ligand to one
of any number of cell surface receptors or antigens, such as
RGD.
Further examples of the targeting module is a chemical
molecule, a small drug molecule or a chromophore molecule, or a protein molecule, or a lectin that are covalently
joined to polymalic acid in constructing the conjugation with
the RNA nanoparticle.
The term "folate" as used herein can comprise, for
example, a genus of well-defined B-vitamin compounds,
including but not limited to, 5-methyltetrahydro folate,
5-formyltetrahydrofolate, dihydrofolate, tetrahydrofolate,
folic acid and other folate compounds. Since folate is an
essential component required during DNA replication and
methylation in highly proliferating cells, many cancer cells,
such as those of the brain, ovary, lung, breast, kidney,
endometrium, colon and bone marrow, over-express FRs to
increase folate uptake (19). Folic acid (FA), a synthetic
oxidized form of folate, has been widely used as a ligand in
various cancer targeting materials (20).
In some embodiments, the presently disclosed subject
matter provides a bioactive agent includes a drug, a fluorescent dye, a chemical, or a combination thereof. In some
embodiments, the bioactive agent includes an imaging module. Non-limiting examples of the imaging module is fluorescent dye, including a non-limiting example Alexa647. In
some embodiments, the bioactive agent is coupled to the
RNA nanostructure molecule. In some embodiments, the
bioactive agent is a therapeutic agent. In some embodiments,
the bioactive agent includes a siRNA, a miRNA, an antimiRNA, a ribozyme RNA, an antisense RNA, or a combination thereof. In some embodiments, the bioactive agent is
directed to a brain tumor marker. Non-limiting examples of
the bioactive agent include siRNA sequence and microRNA
sequence.
RNA interference (RNAi) is a polynucleotide sequencespecific, post-transcriptional gene silencing mechanism
effected by double-stranded RNA that results in degradation
of a specific messenger RNA (mRNA), thereby reducing the
expression of a desired target polypeptide encoded by the
mRNA (see, e.g., WO 99/32619; WO 01/75164; U.S. Pat.
No. 6,506,559; Fire et al., Nature 391:806-11 (1998): Sharp,
Genes Dev. 13:139-41 (1999); Elbashir et al. Nature 411:
494-98 (2001); Harborth et al., J. Cell Sci. 114:4557-65
(2001)). RNAi is mediated by double-stranded polynucleotides as also described hereinbelow, for example, doublestranded RNA (dsRNA), having sequences that correspond
to exonic sequences encoding portions of the polypeptides
for which expression is compromised.
The terms "small interfering RNA", "short interfering
RNA", "small hairpin RNA", "siRNA", and shRNA are
used interchangeably and refer to any nucleic acid molecule
capable of mediating RNA interference (RNAi) or gene
silencing. See e.g., Bass, Nature 411:428-429, 2001;
Elbashir et al., Nature 411:494-498, 2001a; and PCT International Publication Nos. WO 00/44895, WO 01/36646,
WO 99/32619, WO 00/01846, WO 01/29058, WO
99/07409, and WO 00/44914. In one embodiment, the
siRNA comprises a double stranded polynucleotide molecule comprising complementary sense and antisense
regions, wherein the antisense region comprises a sequence
complementary to a region of a target nucleic acid molecule
(for example, a nucleic acid molecule encoding BRCAAl).
In another embodiment, the siRNA comprises a single
stranded polynucleotide having self-complementary sense
and antisense regions, wherein the antisense region comprises a sequence complementary to a region of a target

nucleic acid molecule. In another embodiment, the siRNA
comprises a single stranded polynucleotide having one or
more loop structures and a stem comprising self complementary sense and antisense regions, wherein the antisense
region comprises a sequence complementary to a region of
a target nucleic acid molecule, and wherein the polynucleotide can be processed either in vivo or in vitro to generate
an active siRNA capable of mediating RNAi. As used
herein, siRNA molecules need not be limited to those
molecules containing only RNA, but further encompass
chemically modified nucleotides and non-nucleotides.
In some embodiments, the siRNA molecule of the presently disclosed subject matter is a siRNA molecule that
binds to a single stranded RNA molecule, which is a
messenger RNA (mRNA) that encodes at least part of a
peptide or protein whose activity promotes tumorigenesis,
angiogenesis, or cell proliferation in the brain or spinal cord
of a manimal, or which is a micro-RNA (miRNA) whose
activity promotes tumorigenesis, angiogenesis, or cell proliferation in the brain or spinal cord of a mammal. In some
embodiment of the present disclosure, to interfere oncogenic
coding genes to regress brain tumor growth, the RNA
nano structure molecule silence oncogenes, including but not
limited to, RAS, cMET, HER2. MDM2, PIK3CA, AKT, and
CDK4.
The phrase "brain tumor marker" as used herein refers to
genes or gene products (e.g., RNA molecules or proteins)
which are characteristic of some or all of the cells in brain
cancer. A brain cancer marker with diagnostic value can be
a gene or gene product expressed in normal, non-cancerous
cells, but is characteristic of a type or classification of cancer
by, for example, its over-expression or under-expression as
compared to its expression in normal, non-cancerous cells.
A brain tumor marker with prognostic value is a gene or
gene product for which the over-expression or under-expression confers predictive information about the future
aggressiveness of a cancer and/or its response to therapy at
the time of diagnosis. In a cancer sample, the patterns of
expression of diagnostic and prognostic cancer markers
allow one to accurately identify and determine the future
course of the disease, respectively. Non-limiting examples
of brain tumor biomarkers are described in WO2007069882
(herein incorporated by reference in its entirety).
In one embodiment, the siRNA molecule binds to an
mRNA that encodes at least part of a peptide or protein
whose activity promotes tumorigenesis, angiogenesis, or
cell proliferation, or a combination thereof, in the brain or
spinal cord of a manimal. Such may be the case when the
mRNA molecule encodes a protein in a pro-tumorigenic
pathway, pro-angiogenesis pathway, pro-cell proliferation
pathway, or anti-apoptotic pathway. For example, the protein can be a VEGF pathway protein, EGFR pathway
protein, MGMT pathway protein, RAF pathway protein.
MMP pathway protein, mTOR pathway protein, TGF~
pathway protein, or Cox-2 pathway protein. In one embodiment, the protein is one of the following, including but not
limited to, VEGF, EGFR, PDK, AKT, AGT, RAFI, RAS,
MAPK, ERK, MGMT, MMP-2, MMP-9, PDGF, PDGFR,
IGF-I, HGF, mTOR, Cox-2, or TGF~l. In another embodiment, the protein is VEGF. EGFR. MGMT, MMP-2, MMP9, or PDGF. In still another embodiment, the protein is
RAFI, mTOR, Cox-2, or TGF~l.
In some embodiments, the present disclosure provides
that the bioactive agent is a microRNA sequence. As used
herein, the term "Micro RNAs (miRNAs )" as used herein are
single-stranded, or double stranded non-coding RNAs, at
least about 6 nucleotide in length that can regulate gene
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expression at the post-transcriptional level by either degrading their target mRNAs or inhibiting their translation (See,
e.g. Bartel, D. P., (2004), Cell, 116, 281-297; Liang Z., et al.,
(2013), J Genet. Genomics, 40, 141-142). MiRNAs play
important roles in regulating cell cycle, proliferation, differentiation, metabolism, and apoptosis. A compendium of
microRNA and respective microRNA binding sequences is
available at the miRNA registry. (See, e.g., Griffiths-Jones et
al.
(2006)
Nucl.
Acids
Res.
34:D140-Dl44,
US20140045709, herein incorporate by reference in their
entireties.) In particular embodiments, the microRNA and
microRNA binding sequence employed in the present disclosure are associated with a disease or condition, wherein
an antagonist or agonist to the microRNA would be useful
in preventing or treating the disease or condition. Dysregulation of miRNAs has been implicated in tumor initiation,
progression, and metastasis in several cancer types (See,
Carlin G. A., et al., Nat. Rev. Cancer 2006, 6, 857-866; Di
L. G., et al., Annu. Rev. Pathol. 2014, 9, 287-314; Garzon,
R. et al., Annu. Rev. Med. 2009, 60, 167-179; Iorio, M. V.,
et al., Cancer Res 2005, 65, 7065-7070; Croce, C. M., et al.,
Cell 2005, 122, 6-7.). MiRNAs hold great potentials for
cancer therapy particularly because one miRNA can regulate
a broad set of target genes efficiently and simultaneously,
and can therefore address the heterogeneous nature of cancer. Naturally occurring miRNA further displays reduced
immune response and low toxicity. Both anti-miRNAs to
knockdown oncogenic miRNAs and mimics of miRNAs to
upregulate endogenous miRNAs have been developed as
therapeutic strategies to achieve tumor regression (Henry, J.,
et al. Pharm Res 2011, 28, 3030-3042). However, the major
limiting factor is the ability to specifically deliver these
therapeutic modules to affected cells and tissues. Nanotechnology holds great promise in this regard and several
nanoplatforms have been pursued, but effective strategies to
inhibit tumor progression are still lacking (Grodzinski, P.;
Torchilin, V.; (Editors) Adv. Drug Delivery Rev.: Cancer
Nanotechnology; Volume 66 ed.; Elsevier: 2014.).
In some embodiments, the microRNA or anti-miRNA
sequence is at least about 3 nucleotide in length. In some
embodiments, the miRNA molecule has a length of at least
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides or more. IN
some embodiments, an anti-miRNA or an antagomir of a
miRNAmolecule is at least about 6 nucleotides in length. In
some embodiments, the antagomir of a miRNA molecule
has a length of at least about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30 nucleotides or more.
In some embodiments, to interfere oncogenic miRNA to
regress brain tumor growth, the RNA nanostructure molecule contains anti-miRNA that silences oncogenic miRNAs, including but not limited to, miR-9, miR-l0b, miR-21,
miR-17, and miR-26. In some embodiments, to rescue
down-regulated tumor suppressive miRNAs, RNA nanostructure introduces includes tumor suppressive miRNAs,
including but not limited to, let-7a, miR-l0b, miR-25,
miR-34a, miR-124, miR-145, and miR-181b. MiRNA
sequences are listed below:

-continued
miR-26a,

let-7a,

5

(SEQ ID NO,

8)

5'-UACCCUGUAGAACCGAAUUUGUG-3'

(SEQ ID NO,

9)

(SEQ ID NO,

11)

( SEQ ID NO,

12)

( SEQ ID NO,

13)

( SEQ ID NO,

14)

(SEQ ID NO,

15)

(SEQ ID NO,

16)

5'-AGGCGGAGACUUGGGCAAUUG-3'
miR-34a,

10

5'-UGGCAGUGUCUUAGCUGGUUGU-3'
miR-124,

5'-CGUGUUCACAGCGGACCUUGAU-3'
miR-145,

15

5'-GUCCAGUUUUCCCAGGAAUCCCU-3'
miR-181b,

5'-AACAUUCAUUGCUGUCGGUGGGU-3'
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5'-UCUUUGGUUA UCUAGCUGUA UG-3'
miR-l0b,

10)

5'-UGAGGUAGUAGGUUGUAUAGUU-3'
miR-25,

60
miR-9,

(SEQ ID NO,

5'-UUCAAGUAAUCCAGGAUAGGCU-3'
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In some embodiments, the microRNA includes a locked
nucleic acid (LNA) sequence. In some embodiments, the
microRNAis a LNA-anti-miR21 sequence 5'-+G+A+T+A+
A+G+C+ T CTC CCG GCC GCC ATG GCC GCG GGA T-3'
(SEQ ID NO: 7) (underlined sequence is 8-mer anti-miR21
LNA, and "+" denotes LNA sequence). In some embodiments, the RNA nanostructure contains a strand
LNAl 7_sphl:
5'-+A+G+C+A+C+T +T +TCTCCCGGCCGCCATGGCCGCGGGAT-3' (SEQ ID NO: 17) ("+"
denotes LNA sequence.) In another embodiment, the RNA
nanostructure contains a strand of LNA19a_sphl: 5'-+A+
T+T+T+G+C+A+CCTCCCGGCCGCCATGGCCGCGGGAT-3' (SEQ ID NO: 18) ("+" denotes LNA
sequence.).
In some embodiments, the present disclosure provides
inhibitors of miRNAs (e.g., anti-miR-21). Compositions
comprising such inhibitors and methods for inhibiting miR21 using such inhibitors are also disclosed herein. Any
miRNA inhibitor may be used alone, or with other miRNA
inhibitor(s) known in the art. In some embodiments, the
miRNA inhibitor comprises an antisense molecule. In some
embodiments, the antisense molecule could be a single or a
double stranded sequence. Examples of antisense molecule
include, but are not limited to, siRNAs, triple-helix-forming
agents, ribozymes, RNAi, synthetic peptide nucleic acids
(PNAs), antigenes (agRNAs), LNA/DNAcopolymers, small
molecule chemical compounds, and antisense oligonucleotides.
Further provided, in some embodiments of the presently
disclosed subject matter, is a nucleic acid composition. The
composition includes a therapeutically effective amount of
the artificial RNA nanostructure molecule as disclosed
above. In some embodiments, the composition includes a
pharmaceutically acceptable carrier.
Still further, the presently disclosed subject matter, in
some embodiments, provides a nanoparticle delivery system. The delivery system includes the artificial RNA nanostructure molecule as disclosed above. In some embodiments, the nanoparticle delivery system further includes a
pharmaceutically acceptable carrier.
In another aspect, the presently disclosed subject matter
provides, in some embodiments, a method of treating a brain
tumor in a subject having or at risk of developing a brain
tumor. The method includes administering to the subject a
therapeutically effective amount of a composition comprising an artificial RNA nanostructure molecule as disclosed
above and herein. In some embodiments, the composition
includes a pharmaceutically acceptable carrier.
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Further, in some embodiments, the present disclosure
provides a method of preventing brain tumor recurrence a
subject having or at risk of having brain tumor recurrence.
The method includes administering to the subject a therapeutically effective amount of a composition comprising an
artificial RNA nanostructure molecule as disclosed above
and herein. In some embodiments, the composition includes
a pharmaceutically acceptable carrier.
Brain tumors are a very serious and are among the most
difficult to treat, with a very short survival in patients,
despite administration of the optimal treatment available.
The very unique biological environment of the brain, as
separated by the blood-cerebrospinal fluid barrier (BCFB),
significantly contributes to a range of site-specific cancers in
this organ that require alternative treatment than those
cancers of the remaining human body. Treatment consists
primarily of surgical removal and radiation therapy; chemotherapy is also used, but the range of suitable chemotherapeutic agents is limited, perhaps because most therapeutic
agents do not penetrate the blood-brain barrier adequately to
treat brain tumors. Using known chemotherapeutics along
with surgery and radiation rarely extends survival much
beyond that produced by surgery and radiation alone. Thus
improved therapeutic options are needed for brain tumors.
In some embodiments, the brain tumor is a glioma.
Gliomas are a common type of brain tumor. They arise from
the supportive neuronal tissue comprised of glial cells
(hence the name glioma), which maintain the position and
function of neurons. In some embodiments, gliomas are
classified according to the type of glial cells they resemble:
astrocytomas (including glioblastomas) resemble starshaped astrocyte glial cells, oligodendrogliomas resemble
oligodendrocyte glial cells; and ependymomas resemble
ependymal glial cells that form the lining of fluid cavities in
the brain. In some embodiments, a tumor may contain a
mixture of these cell types, and would be referred to as a
mixed glioma.
As disclosed herein, in some embodiments, the brain
tumor is a glioblastoma. Glioblastomas is the most common
primary brain tumors in adults and are also one of the most
deadly cancers (1 ). The median survival of patients with
glioblastoma is less than 15 months. The poor prognosis is
primarily due to tumor recurrence, which is thought to
originate from a subset of cancer stem cells that survive the
primary treatments. Recent studies suggested that glioblastoma stem cell survived the therapeutic stresses and become
more aggressive when they recur, developing resistance to
the primary chemotherapy. In some embodiment, the presently disclosed subject matter provides a method of administering the RNA nanostructure composition as disclosed
herein to both brain tumor cells and glioblastoma stem cells
to treat the primary brain tumor and prevent tumor recurrence.
In some embodiments, the method(s) as disclosed herein
includes administering to the subject a therapeutically effective amount a composition. The composition includes an
artificial RNA nanostructure molecule, wherein the molecule includes a multiple branched RNA junction motif
comprising at least one RNA oligonucleotide, a brain tumor
targeting module coupled to an RNA junction motif, and at
least one therapeutic agent coupled to the RNA junction
motif. In some embodiments, the composition further
includes a pharmaceutically acceptable carrier. In some
embodiments, the bioactive agent comprises a therapeutic
agent. In some embodiments, the RNA oligonucleotide
comprises at least one chemical modification at the 2'
position. Non-limiting examples of the modification com-

prises 2'Fluoro, 2'Amine, 2'O-Methyl, or a combination
thereof. In some embodiments, the motif is a three-branched
RNA junction motif. An non-limiting example of the threebranched RNA junction motif comprises a packaging RNA
(pRNA) three-way junction (3WJ) motif. In some embodiments, the diameter of the molecule is at least about 40 nm
or less. In some embodiments, the molecule has a zeta
potential ranging from about -50 m V to about 50 m V. In
some embodiments, the multiple branched RNA includes a
nucleotide 5'-UUG CCA UGU GUA UGU GGG AUC CCG
CGG CCA UGG CGG CCG GGA G-3' (SEQ ID NO: 6). In
another embodiment, the multiple branched RNA comprises
sequence 5'-GATAAGCT CTC CCG GCC GCC ATG GCC
GCG GGA T-3' (SEQ ID NO: 7). In some embodiments, a
branch of the three-branched RNA junction motif includes at
least one ofana3WJ RNA module (SEQ ID NO: 1); a b3WJ
RNA module (SEQ ID NO: 2); or a c3WJ RNA module
(SEQ ID NO: 3).
In some embodiments, the brain tumor targeting module
in the method(s) of the presently disclosed subject matter
includes a ligand that binds to at least one brain tumor cell
surface marker. In some embodiments, the ligand binds to a
folate receptor, an EGFR, a transferrin receptor, an RGD, or
a combination thereof. In some embodiments, the ligand
comprises an aptamer. In some embodiments, the targeting
module comprises a folate. Non-limiting examples offolate
include folic acid, 5-methyltetrahydro folate, 5-formyltetrahydrofolate, dihydrofolate, tetrahydrofolate, or other folate
compounds.
In some embodiments, the therapeutic agents in the method(s) of the presently disclosed subject matter includes a
drug, a fluorescent dye, a chemical, or a combination
thereof. Further, the therapeutic agent includes a siRNA, a
miRNA, an anti-miRNA, a ribozyme RNA, an antisense
RNA, or a combination thereof. In some embodiments, the
therapeutic agent is directed to a brain tumor marker. In
some embodiments, the therapeutic agent is a siRNA
sequence, or a microRNA sequence. In some embodiments,
the microRNA sequence is at least 6 nucleotide in length.
Non-limiting example of the microRNA is a locked nucleic
acid (LNA) sequence. An example of the LNA sequence is
is a LNA-miR21 sequence as described herein. In some
embodiments, the siRNA binds to a mRNA sequence of a
gene that promotes tumorigenesis, angiogenesis, cell proliferation, or a combination thereof, in the brain or spinal cord.
In some embodiments, the siRNA binds to a mRNA molecule that encodes a protein including pro-tumorigenic pathway proteins, pro-angiogenesis pathway proteins, pro-cell
proliferation pathway proteins, anti-apoptotic pathway proteins, or a combination thereof. In some embodiments, the
mRNA molecule encodes a protein including VEGF pathway proteins, EGFR pathway proteins, MGMT pathway
proteins, Rafi pathway proteins, MMP pathway proteins,
mTOR pathway proteins, TGF~ pathway proteins, or Cox-2
pathway proteins, or a combination thereof. In some
embodiments, the protein includes VEGF, EGFR, POK,
AKT, AGT, RAF, RAS, MAPK, ERK, MGMT, MMP-2,
MMP-9, PDGF, PDGFR, IGF-I, HGF, mTOR, Cox-2 or
TGF~l.
Further, in some embodiments of the methods, the present
subject matter relates to a method to target and deliver
therapeutic siRNA to brain tumors using FA-conjugated
pRNA-3WJ RNP. First, intracranial tumor xenograft models
in mice was established and then systemically administered
RNPs through the tail vein. Based on fluorescence imaging,
It is demonstrated that the pRNA-3WJ RNP efficiently
targeted and internalized into brain tumor cells through
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FR-mediated endocytosis with little or no accumulation in
adjacent healthy brain cells. Gene silencing by the RNPs
was also demonstrated within the luciferase gene expressing
brain tumors. More importantly, pRNA-3WJ RNPs were
also capable of targeting brain tumor stem cells derived from
a human patient. The data demonstrate that artificially
engineered RNPs can specifically target brain tumor cells,
including glioblastoma stem cells, and deliver functional
siRNA and therapeutic microRNAs (miRNAs) (21).
The term "treatment" and "prophylaxis" as used herein is
to be considered in its broadest context. The term "treatment" does not necessarily imply that a host is treated until
total recovery. Similarly, "prophylaxis" does not necessarily
mean that the subject will not eventually contract a disease
condition. Accordingly, treatment and prophylaxis include
amelioration of the symptoms of a particular condition or
preventing or otherwise reducing the risk of developing a
particular condition. The term "prophylaxis" may be considered as reducing the severity of onset of a particular
condition. "Treatment" may also reduce the severity of an
existing condition.
The term "pharmaceutically acceptable carrier" as used
herein refers to a diluent, adjuvant, excipient, or vehicle with
which a heterodimeric probe of the disclosure is administered and which is approved by a regulatory agency of the
federal or a state govermnent or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use
in animals, and more particularly in humans. Such pharmaceutical carriers can be liquids, such as water and oils,
including those of petroleum, animal, vegetable, or synthetic
origin, such as peanut oil, soybean oil, mineral oil, sesame
oil, and the like. The pharmaceutical carriers can be saline,
gum acacia, gelatin, starch paste, talc, keratin, colloidal
silica, urea, and the like. When administered to a patient, the
heterodimeric probe and pharmaceutically acceptable carriers can be sterile. Water is a useful carrier when the
heterodimeric probe is administered intravenously. Saline
solutions and aqueous dextrose and glycerol solutions can
also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include
excipients such as glucose, lactose, sucrose, glycerol monostearate, sodium chloride, glycerol, propylene, glycol, water,
ethanol, and the like. The present compositions, if desired,
can also contain minor amounts of wetting or emulsifying
agents, or pH buffering agents. The present compositions
advantageously may take the form of solutions, emulsion,
sustained release formulations, or any other form suitable for
use.
The term "therapeutically effective amount," as used
herein, refers to the amount of a composition containing
administered to a patient already suffering from a disease,
condition, or disorder, sufficient to cure or at least partially
arrest, or relieve to some extent one or more of the symptoms of the disease, disorder, or condition being treated. The
effectiveness of such compositions depend upon conditions
including, but not limited to, the severity and course of the
disease, disorder, or condition, previous therapy, the
patient's health status and response to the drugs, and the
judgment of the treating physician. By way of example only,
therapeutically effective amounts may be determined by
routine experimentation, including but not limited to a dose
escalation clinical trial.
The specific therapeutically effective dose level for any
particular patient will depend upon a variety of factors
including the disorder being treated and the severity of the
disorder; the specific composition employed; the age, body
weight, general health, sex and diet of the patient; the time

of administration; the route of administration; the rate of
excretion of the specific compound employed; the duration
of the treatment; drugs used in combination or coincidental
with the specific compound employed and like factors well
known in the medical arts. For example, it is well within the
skill of the art to start doses of a compound at levels lower
than those required to achieve the desired therapeutic effect
and to gradually increase the dosage until the desired effect
is achieved. If desired, the effective daily dose can be
divided into multiple doses for purposes of administration.
Consequently, single dose compositions can contain such
amounts or submultiples thereof to make up the daily dose.
The dosage can be adjusted by the individual physician in
the event of any contraindications. Dosage can vary, and can
be administered in one or more dose administrations daily,
for one or several days. Guidance can be found in the
literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a "prophylactically effective
amount"; that is, an amount effective for prevention of a
disease or condition.
As used herein, the term "subject" refers to a target of
administration of the pharmaceutical composition. The subject of the herein disclosed methods can be a vertebrate, such
as a mammal, a fish, a bird, a reptile, or an amphibian. Thus,
the subject of the herein disclosed methods can be a human
or non-human. Thus, veterinary therapeutic uses are provided in accordance with the presently disclosed subject
matter. As such, the presently disclosed subject matter
provides for administration to mammals such as humans and
non-human primates, as well as those mammals of importance due to being endangered, such as Siberian tigers; of
economic importance, such as animals raised on farms for
consumption by humans; and/or animals of social importance to humans, such as animals kept as pets or in zoos.
Examples of such animals include but are not limited to:
carnivores such as cats and dogs; swine, including pigs,
hogs, and wild boars; ruminants and/or ungulates such as
cattle, oxen, sheep, giraffes, deer, goats, bison, and camels;
rabbits, guinea pigs, and rodents. Also provided is the
treatment of birds, including the treatment of those kinds of
birds that are endangered and/or kept in zoos, as well as
fowl, and more particularly domesticated fowl, i.e., poultry,
such as turkeys, chickens, ducks, geese, guinea fowl, and the
like, as they are also of economic importance to humans.
Thus, also provided is the treatment of livestock, including,
but not limited to, domesticated swine, ruminants, ungulates, horses (including race horses), poultry, and the like.
The term does not denote a particular age or sex.
Suitable methods for administering to a subject an effective amount of the composition in accordance with the
methods of the present invention include but are not limited
to systemic administration, parenteral administration (ineluding intravascular, intramuscular, intraarterial administration), oral delivery, buccal delivery, subcutaneous administration, inhalation, intratracheal installation, surgical
implantation, transdermal delivery, local injection, and
hyper-velocity injection/bombardment. Where applicable,
continuous infusion can enhance drug accumulation at a
target site (see, e.g., U.S. Pat. No. 6,180,082).
The particular mode of drug administration used in accordance with the methods of the present invention depends on
various factors, including but not limited to the vector and/or
drug carrier employed, the severity of the condition to be
treated, and mechanisms for metabolism or removal of the
drug following administration.
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The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may include compilations of data
that are representative of data gathered at various times
during the course of development and experimentation
related to the presently disclosed subject matter.

and computational prediction implies that each protruded
branch of FA-pRNA-3WJ-si(luc) RNP was avoided from
averaging three dimensions due to rapid motion of nanoparticles in solution. Another factor that needs to be
addressed for successful systemic in vivo application of
nanoparticles is freedom from aggregation to avoid rapid
clearance from the body and diminished specific interaction
between the conjugated ligand and cellular target receptors.
Aggregation depends largely on the surface charge of nanoparticles and the surface of RNA is indeed highly charged.
Aggregation will also change the surface charge proportional to the extent of size increase. To determine the
aggregation extent, FA-pRNA-3WJ-si(luc) RNP was subjected to zeta potential analysis to measure the particle
surface charge. Zeta potential of FA-pRNA-3WJ-si(luc)
RNP in PBS solution was measured as a single peak at
-15.8±5.6 mV (FIG. lD), indicating that most FA-pRNA3 WJ-si(luc) RNP exist as a single form without aggregation.
These physical properties favor the FA-pRNA-3WJ-si(luc)
RNP for systemic in vivo application.
Human glioblastoma cells are known to overexpress FR,
while normal brain cells show no FR expression (17-19). To
determine the specific recognition and binding capability of
FA-pRNA-3WJ-si(luc) RNP towards human glioblastoma
cells, firstly association of FA-Alexa647-pRNA-3WJ with
U87EGFRvIII cell was tested in vitro in comparison to
FA-free control RNP (Alexa647-pRNA-3WJ). Flow cytometry analysis showed a higher association of FA-Alexa647pRNA-3WJ with U87EGFRvIII cells (63.1±4.5%) than that
of Alexa647-pRNA-3WJ (40.3±3.7%) (student t-test,
p<0.001, n=4) (FIG. 2A). When FRs ofU87EGFRvIII cells
were pre-masked by incubating with 1 mM free-folate for 1
hr of culture before the RNP binding, the association
between FA-Alexa647-pRNA-3WJ and U87EGFRvIII cells
was decreased to an extent similar to the negative control
Alexa647-pRNA-3WJ (FIG. 5), indicating that the association between FA-Alexa647-pRNA-3WJ and U87EGFRvIII
cells was FR dependent. The FR-mediated specific binding
of FA-Alexa647-pRNA-3WJ to U87EGFRvIII cells was
further confirmed by visualizing the Alexa647 signal from
surface-cultured U87EGFRvIII cells treated with FA-Alexa647-pRNA-3WJ RNP under confocal fluorescence
microscope. Higher fluorescence intensity of Alexa647 dye
was observed from U87EGFRvIII cells treated with FA-Alexa647-pRNA-3WJ than those with control RNP (Alexa647-pRNA-3WJ) (FIG. 2B). Again, the FA-dependent
association of FA-Alexa647-pRNA-3WJ RNP was abolished by pre-treatment of U87EGFRvIII cells with 1 mM
free folate in culture medium (FIG. 2B). The FR-mediated
specific association between FA-Alexa647-pRNA-3WJ
RNP and human glioblastoma cell was also observed with
other glioblastoma cell lines including T98G (FIG. 6). Taken
together, FA-conjugated pRNA-3WJ RNP has the capability
to recognize and bind to human brain tumor cells through
FR.
Next, we tested whether FA-pRNA-3WJ RNP can specifically target tumor cells in vivo using an orthotropic
mouse model of glioblastoma. On the 14th day post
U87EGFRvIII cell implantation into nude mouse brain,
intracranial tumor growth in mice was determined by MRI
(FIG. 2C, top) and randomly separated into three groups for
injection of PBS, Alexa647-pRNA-3WJ as two negative
controls and FA-Alexa647-pRNA-3WJ as experimental.
Each group of mice (n=4) was injected via tail vein (1 mg/kg
of RNP in 100 µL of PBS). Fifteen hours post injection, the
mice brains were dissected and subjected to fluorescence
imaging to detect the Alexa647 signal from RNP. A higher
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EXAMPLES
Example 1
Glioblastoma is one of the most deadly cancers. Systemic
siRNA administration to treat glioblastoma patients requires
a robust and efficient delivery platform without immunogenicity. This example report the application of RNA nanotechnology based on pRNA 3-way-junction (3WJ) of bacteriophage phi29 for glioblastoma targeting. Multivalent
folate (FA)-conjugated RNAnanoparticles were constructed
to harbor siRNA. The resulted FA-pRNA-3WJ RNA nanoparticle (RNP) specifically targeted and entered human
malignant glioblastoma cells in vitro and intracranial glioblastoma xenografts in vivo. Systemically injected
FA-pRNA-3WJ RNPs successfully targeted and delivered
siRNA into brain tumor cells in mice, and efficiently reduced
luciferase reporter gene expression (4-fold lower than control). The FA-pRNA-3WJ RNA nanoparticles were also
demonstrated to target both human patient-derived glioblastoma stem cells, which are thought to be responsible for
tumor initiation, drug resistance and deadly recurrence, and
the derived brain tumor in mouse model without accumulation in adjacent normal brain cells, nor other major internal
organs. The results of this study may promise a successful
clinical application of pRNA-3WJ RNP for specific delivery
of therapeutics such as siRNA, microRNA and/or chemotherapeutic drugs into glioblastoma cells without inflicting
collateral damage to healthy tissues.
Results and Discussion
This study was to assess application ofpRNA-3WJ RNP
for systemic delivery of therapeutic RNA, such as siRNA
and miRNA, into brain tumors in a mouse model system. For
targeted delivery of siRNA into brain tumors, a multifunctional RNP was constructed, as previously described (7,12,
13,22), using a scaffold based on pRNA sequences of phi29
bacteriophage with slight modifications (see Materials and
Methods). Three RNA modules individually transcribed in
vitro or synthesized chemically were mixed at equal molar
ratio and formed three-branched RNP via one-step selfassembly. Each RNA module was designed to carry a
functional moiety: 1) FA as the FR targeting ligand; 2)
fluorophore Alexa647 as the imaging agent; and 3)
luciferase siRNA as the gene silencing functional moiety or
scrambled RNA as a negative control (FIG. lA) (7,12,13,
22). The resulting RNP was named FA-pRNA-3WJ-si(luc)
RNP. Observation of the self-assembled FA-pRNA-3WJ-si
(luc) RNP under atomic force microscopy (AFM) revealed
the formation of homogeneous three-branched architectures
with 3WJ core in the center (FIG. lB), confirming the
previous reports that modifications on each RNA module did
not abrogate the shape-controlled self-assembly to retain the
pRNA-3WJ core structure essential for homogeneous uniformed RNP formation. Dynamic light scattering (DLS)
determined average hydrodynamic diameters ofFA-pRNA3WJ-si(luc) RNP to be 5.2±1.2 nm (FIG. lC), which was
smaller than the predicted size (10x4x2 nm) calculated by
RNA folding software based on expected duplex helix
parameters and base pair lengths of the three individual
RNA modules. The discrepancy between DLS measurement
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fluorescence signal of Alexa647 was observed in the brains
of mice injected with FA-Alexa647-pRNA-3WJ than that in
the mice brains injected with control RNP (Alexa647pRNA-3WJ) (FIG. 2C). ANOVA analysis on the fluorescence intensity from each group (n=4) normalized by their
tumor volumes (Alexa647 intensity/tumor volume) confirmed the significant increase in average fluorescence intensity in the mouse brains treated with FA-Alexa647-pRNA3WJ (2.052±0.416, s.e.m.) compared to Alexa647-pRNA3WJ (1.014±0.279, s.e.m.) (p=0.019) with respect to PBS
(1.000±0.298, s.e.m.) (FIG. 2D). The brain tumor region
was frozen sectioned (10 µm thick) and further examined
under a fluorescence confocal microscope. It revealed that
FA-Alexa647-pRNA-3WJ RNP was mostly associated with
counterstained brain tumor cells (Supplementary FIG. 7).
These in vivo data strongly indicated that systemically
injected FA-Alexa647-pRNA-3WJ RNP can travel to brain
tissue, and successfully recognize and bind human glioblastoma cells through FA-FR interaction, rather than randomly
distribute throughout the entire brain tissues.
After binding to target glioblastoma cells, RNP needs to
internalize to deliver its cargo, siRNA, for successful target
gene silencing, which is the most critical property for any
nanoparticle to claim its therapeutic application. In order to
test whether siRNA-loaded FA-3WJ RNP can silence the
target gene in glioblastoma cells in mouse brain after systemic administration, we set up a luciferase-based gene
expression reporter system by implanting luciferase geneexpressing U87EGFRvIII cells (U87EGFRvIII-Luc) in
mouse brain. For a preliminary in vitro test, U87EGFRvIIILuc cells were incubated for 72 hrs in culture medium
containing a range between O and 400 nM of FA-pRNA3WJ-si(Luc) or scrambled RNA-conjugated control
FA-pRNA-3WJ-si(Scrm) RNPs without any transfection
agent. After 72 hrs, FA-pRNA-3WJ-si(Luc) clearly reduced
luciferase activity in a concentration dependent manner. At
400 nM, average luciferase activity in U87EGFRvIII-Luc
cells incubated with FA-pRNA-3WJ-si(Luc) was decreased
about five folds (0.214±0.210, s.e.m.) with respect to O nM.
However, FA-pRNA-3WJ-si(Scrm) did not significantly
reduce luciferase activity in the cells (0.876±0.056, s.e.m.)
compared to O nM. The difference of luciferase activity at
400 nM between FA-pRNA-3WJ-si(Luc) and FA-pRNA3WJ-si(Scrm) was statistically significant (p=0.00 6 ) (FIG.
3A). For in vivo test, intracranial tumor in mice was induced
by implanting U87EGFRvIII-Luc cells. Bioluminescence
signal measured from the resulted brain tumor is expected to
correlate with tumor growth. When a group of brain tumorbearing mice (n=5) were systemically injected with
FA-pRNA-3WJ-si(Scrm) (1 mg/kg in 100 µL of PBS) for a
total of three times over 6 days, the luciferase activity
rapidly increased as the tumor grew indicating no effect of
the control RNP on luciferase gene expression. However,
luciferase activity from the group of mice (n=5) injected
with FA-pRNA-3WJ-si(Luc) was observed to increase very
slowly over time (FIG. 3B). After 3 injections, the luciferase
activity from the mice injected with FA-pRNA-3WJ-si(Luc)
was significantly lower (p=0.007) than that from the control
group mice injected with FA-pRNA-3WJ-si(Scrm). The
luciferase activity from the tested mice at day 13 post tumor
implantation was mostly lower than that from the mice
treated with FA-pRNA-3WJ-si(Scrm) (FIG. 3C). However,
MRI revealed that the relative tumor size between those two
groups was statistically insignificant (1.160±0.352 mm3 ,
s.e.m. with respect to 1.000±0.300 mm3 in negative control
group) (p=-0.468, n=5) (FIG. 3D). When their luciferase
activity was normalized by the tumor volumes, the relatively

averaged luciferase activity over tumor volumes from the
mice treated with FA-pRNA-3WJ-si(Luc) (0.255±0.040
Luminescence Radiance [p/s/cm2 /sr]/tumor volume [mm3 ],
s.e.m.) was significantly lower compared to the control mice
group treated with FA-pRNA-3WJ-si(Scrm) (1.000±0.410
Luminescence Radiance [p/s/cm2 /sr]/tumor volume [mm3 ],
s.e.m.) (p=0.015, n=5) (FIG. 4E). These data strongly indicated that FA-pRNA-3WJ RNP not only specifically targeted glioblastoma cells, but also successfully internalized
into the cells and delivered the cargo siRNA. The delivered
siRNA, more importantly, remained functionally intact for
the whole time of systemic delivery, confirming both stability and therapeutic efficacy of the FA-pRNA-3WJ RNPs.
The data successfully demonstrated the therapeutic usability
as a siRNA delivery system for glioblastoma treatment.
In clinical settings, glioblastomas are notorious for their
frequent recurrence with increased aggressiveness after initial therapy, resulting in poor survival rates. It has been
hypothesized that glioblastoma stem cells tend to survive the
initial treatment and induce tumor recurrence, meaning that
any therapeutic strategy lacking the ability to kill glioblastoma stem cells would not prevent recurrences (23). The
potential of FA-pRNA-3WJ RNPs to target glioblastoma
stem cells and their derived tumor cells was investigated. We
used human glioblastoma patient-derived primary neurosphere cells, named "1123", which has been shown to
possess stem cell-like characteristics including a high level
of CD44 expression, self-renewal capability and tumorigenicity when implanted in mouse brain (24-26). First, the
CD44+ 1123 cells, maintained in serum-free sphere culture
medium, were incubated in vitro with 200 nM of either
FA-Alexa647-pRNA-3WJ or Alexa647-pRNA-3WJ RNPs.
Flow cytometry analysis revealed higher FA-Alexa647pRNA-3WJ binding to the 1123 cells than control RNP
(Alexa647-pRNA-3WJ) (FIG. 4A). Compared to PBStreated 1123 cells, 33.2±0.8% of CD44+ 1123 cells were
positively associated with FA-Alexa647-pRNA-3WJ RNP.
However, Alexa647-pRNA-3WJ control RNP was associated with only 12.7±0.4% of CD44+ 1123 cells. The difference between FA-Alexa647-pRNA-3WJ and Alexa647pRNA-3WJ was statistically significant (p<0.0001).
For systemic assessment, a group of mice was then
implanted with 1123 cells to induce intracranial brain tumor.
Determined by MRI, mice bearing a similar size of brain
tumors were then injected with PBS, Alexa647-pRNA-3WJ
or FA-Alexa647-pRNA-3WJ RNPs in 100 µL of PBS
through the tail vein. Fifteen hours post injection, the brains
were dissected out and subjected to fluorescence imaging.
Higher accumulation of FA-Alexa64 7-pRNA-3 WJ RNP was
observed in the tumor region, while less accumulation of
Alexa647 signal was observed from the brains treated with
either control RNP (Alexa647-pRNA-3WJ) or PBS (FIG.
4B). When two different dosages of FA-Alexa647-pRNA3WJ RNPs (20 or 100 pig/mouse) were tested in a group of
mice bearing small sized tumors, fluorescence signals were
proportional to the amount of RNPs injected (Supplementary FIG. 8). These observations suggests that FA-Alexa647pRNA-3WJ RNP can also recognize and target human
glioblastoma stem cells and their derived tumor cells
through FA-FR specific interaction. Throughout these studies, a fluorescence signal from the groups treated with
FA-free 3WJ-pRNA control RNP was also observed
although the extents were always lower than the groups
treated with FA-3WJ-pRNA RNP. This might be explained
by the nature of tumor induced from human patient derived
stem cell-like glioblastoma cells, in which the aggressive
hypervasculature leaves a large portion of blood vessels as
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"leaky" as they are poorly finished before forming a tight
junction of the BBB, also called the EPR (enhanced permeability and retention) effect (27).
To assess the biodistribution profile of the pRNA-3WJ
RNP throughout the body after systemic administration,
major internal organs, including heart, lung, liver, spleen and
kidney, were also collected together with brain and subjected
to fluorescence imaging. Compared to brain, no significant
fluorescence signal was detected from the internal organs
except kidney (FIG. 4C). The biodistribution profile of
FA-pRNA-3WJ RNP after its systemic administration was
consistent with the previous report (28), in that FA-conjugated drugs that failed to target tumor cells are rapidly
cleared from a mouse body (t 112 <l Omin) through the kidney,
reducing the safety concern of unbound pRNA-3WJ nanoparticles circulating in the blood (7, 12-14).
For successful clinical application of pRNA-3WJ RNP for
human glioblastoma detection and treatment, it was critical
to evaluate its capability to access brain tumor cells by
discriminating them from adjacent normal brain cells, and to
have favorable biodistribution. To address those two goals,
the most critical checkpoints deciding the drugability of the
pRNA-3WJ nanoparticles, we employed an orthotropic
intracranial glioblastoma model system in mice. According
to our observations, it was clear that FA-conjugated
FA-pRNA-3WJ RNP can target human glioblastoma cells
through FA-FR specific interaction-mediated endocytosis by
distinguishing glioma cells from adjacent normal brain cells.
A series of in vitro experiments indicated that such targeting
in vivo was not obviously a result of non-specific accumulation for two reasons: 1) association of FA-pRNA-3WJ
RNP with glioblastoma cells was ligand-dependent; and 2)
the association was mediated through FA-FR specific interaction, since free folate pre-treatment interfered with the
specific interaction between FA and FRs on the targeted
cells. This suggests that FA-pRNA-3WJ RNP can target and
accumulate in FR+ glioblastoma cells. Taken together with
the fact that our brain imaging data were collected 15 hrs
post injection of FA-3WJ RNA nanoparticles and the
luciferase gene silencing effect was seen for days, these data
suggest that FA-pRNA-3WJ RNP can survive in the body by
retaining the chemical integrity of cargo siRNA until it
reaches the brain. Most importantly, the therapeutic delivery
by the FA-3WJ RNA nanoparticles was clearly demonstrated by targeting endogenous luciferase mRNAs as a
reporter system (FIG. 3). The decreased luciferase activity
observed from a group of mice injected with FA-3WJpRNA-si(Luc) RNP clearly answered questions towards the
capability of the FA-3WJ RNP regarding: 1) specific targeting to brain tumor cells; 2) internalization into brain tumor
cells; and 3) releasing the functional moiety (siRNA against
luciferase mRNA). In addition, the targeting capability of
pRNA-3WJ nanoparticles for both brain tumor cells and
glioblastoma stem cells through a FA-FR mediated manner
will overcome the weak point of conventional brain tumor
therapies which largely relies on surgical debulking and
less-specific toxic drugs with radiation. In summary, our
current study successfully demonstrated the drugability of
FA-conjugated pRNA-3WJ RNP as therapeutic gene delivery for clinical applications to meet the urgent need of new
strategies to target and kill both glioblastoma stem cells and
their derived tumor cells. Due to the ease and flexibility of
modification of each RNA module, any drug conjugation
and siRNA can be loaded to the RNP as therapeutic functionalities. Recently, microRNAs have been found to
involve in pathological process in glioblastoma making
them as promising therapeutic targets (29-32). Since size

and working mechanism of miRNAs are similar to those of
siRNAs (21), therapeutic miRNAs also can be considered to
be loaded onto the pRNA-3WJ-RNP.
Methods
Construction of FA-Alexa647-pRNA-3Wj-si(Luc) RNP
Multifunctional pRNA-3WJ RNP was prepared as previously described (7,12,13,22) with slight modifications. In
brief, three RNA modules, named a3 wJ (5'-UUGCCAUGUGUAUGUGGG-3' (SEQ ID NO: 1)), b 3 wJ (5'-CCCACAUACUUUGUUGAUCC-3' (SEQ ID NO: 2)), and c 3 wJ
(5'-GGAUCAAUCAUGGCAA-3' (SEQ ID NO: 3)), were
transcribed in vitro or synthesized chemically using 2'-F
modified nucleotides and purified separately to homogeneity. For the current study, each RNA module was further
modified as following: module a3 wJ was extended with
luciferase siRNA sequences sense: 5'-CUUACGCUGAGUACUUCGAUU-3' (SEQ ID NO: 4) and anti-sense:
5'-UCGAAGUACUCAGCGUAAGUU-3' (SEQ ID NO: 5),
or scrambled as negative control; module b 3 wJ was conjugated with FA at the 3' end; and module c 3 wJ was conjugated
with fluorophore Alexa647 (Alexa Fluor® 647, Invitrogen)
at the 3' end. The three RNA modules were mixed at equal
molar ratio to form one-step self-assembly. The self-assembled FA-Alexa647-pRNA-3WJ-si(Luc) RNPs were
purified from 6 M urea-containing PAGE and frozen at -80°
C. after reconstituted in PBS. To obtain the designated
concentration for each experiment, the RNPs were further
diluted in PBS before use.
Characterization of Self-Assembled FA-Alexa647-pRNA3WJ-si(Luc) RNP
Three dimensional structure and shape of the final form of
self-assembled FA-Alexa647-pRNA-3WJ-si(Luc) RNP was
analyzed by atomic force microscopy (AFM) imaging as
described previously. 7 •12 •13 •22 Apparent hydrodynamic sizes
and zeta potential of pre-assembled FA-Alexa647-pRNA3 WJ-si(Luc) RNP (1.5 µM) in PBS buffer was measured by
Zetasizer nano-ZS (Malvern Instrument) at 25° C. The laser
wavelength was 633 nm. The data were obtained from three
independent measurements.
Human Glioblastoma Cells and Human Patient-Derived
Glioblastoma Stem Cells
Human glioblastoma cells,
U87EGFRvIII
and
U87EGFRvIII-Luc (expressing luciferase reporter gene),
were obtained from Dr. Webster Cavenee (Ludwig Cancer
Institute, San Diego, Calif.). Both cells were maintained in
DMEM/10% FBS/penicillin/streptomycin. Human glioblastoma patient-derived glioblastoma stem cell "1123" was
cultured in DMEM/F12 (Invitrogen) supplemented with
B27 (1:50), heparin (5 mg/mL), basic FGF (bFGF) (20
ng/mL), and EGF (20 ng/mL). Growth factors (bFGF and
EGF) were added twice a week (24).
Intracranial Human Glioblastoma Xenografts from Human
Glioblastoma Cells and Human Patient-Derived Glioblastoma Stem Cells
Six weeks old athymic female nu/nu mice (Jackson Laboratory, Bar Harbor, Me.) were housed and handled in accordance with the Subcommittee on Research Animal Care of
the Ohio State University guidelines approved by the Institutional Review Board. All mice were fed folate-free diet
(Harlan, Indianapolis, Ind.) for at least two weeks before
tumor implantation. Intracranial human glioblastoma xenograft tumor was induced by implanting human glioblastoma
cell U87EGFRvIII or human patient-derived glioblastoma
stem cells (lxl0 5 cells per mouse), as described previously
(33). Two weeks post intracranial tumor implantation, the
location and size of the implanted tumors were determined
by magnetic resonance imaging (MRI).
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Magnetic Resonance Imaging (MRI) for Location and Size
of Implanted Brain Tumor in Mice
On the indicated day post-surgery of intracranial tumor
injection, the location and size of the implanted tumors were
determined by magnetic resonance imaging (MRI). Mouse
was anesthetized with 2.5% isoflurane mixed with 1 Umin
carbogen (95% 0 2 with 5% CO 2 ), then maintained with 1%
isoflurane thereafter. Maintaining core temperature using a
warm water bath, imaging was performed using a Bruker
Biospin 94/30 magnet (Bruker Biospin, Karlsruhe, Germany). Mice were injected with Magnevist, gadoliniumbased contrast agent (Bayer Health Care Pharmaceuticals,
Wayne, N.J.) by an i.p. administration with 0.5 mmol/kg
dose, then positioned in the magnet. T2-weighted RARE
imaging was collected using a sequence (TR=3524 ms,
TE=36 ms, rare factor=8, navgs=2, FOV=20x20 mm, 0.5
mm slice thickness). Region-of-interest (ROI) was manually
outlined based on contrast in signal intensity between brain
and tumor tissue.
Fluorescence Confocal Microscopy for In Vitro and In Vivo
RNP Binding
For the in vitro targeting test ofpRNA-3WJ RNP, 2xl0 3
of U87EGFRvIII (malignant human glioblastoma) cells in
200 µL were plated in Lab-TekII 8-well chamber slide
(Nurre, Rochester, N.Y.). The next day, the cells were
washed with PBS and incubated with 200 nM of either
FA-Alexa647-pRNA-3WJ RNP or control RNP (Alexa647pRNA-3WJ) in 200 µL of culture media for 2 hrs at 37° C.
in a CO 2 incubator. To block cellular FRs by free folate,
PBS-washed cells were pre-treated with 1 mM free folate in
200 µL of culture media for 1 hr at 3 7° C. in a CO 2 incubator
before RNP treatment. After washing with PBS, the RNPtreated cells were fixed in 4% paraformaldehyde (PFA)
solution for 2 hrs at 4° C. The cytoskeleton of the fixed cells
was stained by Alexa Fluor 488 Phalloidin (Invitrogen,
Grand Island, N.Y.) for 30 min at room temperature and the
nucleus stained with 0.01% DAPI solution for 10 min at
room temperature. The cells were then rinsed with PBS for
3xl 0 min and mounted with PermaFluor Aqueous Mounting
Medium (Thermo Scientific). Fluorescence microscopy was
performed using Olympus 4-filter-based Fluo View FVl 000Filter Confocal Microscope System (Olympus Corp.) at the
wavelengths of 461 nm (for the cell nucleus stained by
DAPI), 530 nm (for the cytoskeleton stained by Alexa Fluor
488 Phalloidin) and 665 nm (fortheAlexa647). Images were
analyzed by Olympus FluoView Viewer software ver. 4.0
(Olympus). For in vivo targeting, the brain tumor xenograft
collected 15 hrs after RNP injection was fixed in 4% PFA
with 10% sucrose in PBS overnight at 4° C. and embedded
in Tissue-Tek® O.C.T. compound (Sakura Finetek USA,
Inc., Torrance, Calif.) for frozen sectioning (10 µm thick).
The sectioned samples were mounted by ProLong® Gold
Antifade Reagent with DAPI (Life Technologies Corporation, Carlsbad, Calif.) overnight. The fluorescent images
were obtained using FluoView FVl000-Filter Confocal
Microscope System (Olympus Corp.).
Flow Cytometry for In Vitro RNP Binding
Flow cytometry analysis was performed for in vitro
targeting by pRNA-3WJ RNP in malignant human glioblastoma (U87EGFRvIII) and glioblastoma stem cells (1123).
The cells were plated in 6-well plate one day before RNP
binding. After washing with PBS, the cells were incubated
with 200 nM of either FA-Alexa647-pRNA-3WJ RNP or
Alexa647-pRNA-3WJ RNP in 200 µL of culture media for
2 hrs at 37° C. in a CO 2 incubator. For blocking cellular FRs
by free folate, the PBS-washed cells were pre-treated with 1
mM of free folate in 200 µL of culture media for 1 hr in 3 7°

C. CO 2 incubator before RNP treatment. After washing with
PBS, the cells were harvested by trypsinization and fixed in
4% PFA solution for 2 hrs at 4° C. The cells were washed
with PBS for 3 times at room temperature, then subjected to
Flow Cytometry analysis using BD FACS Aria-III Cell
Sorter. The data were analyzed by FlowJo 7.6.1 software.
Systemic Injection ofRNPs to Intracranial Human Glioblastoma Xenograft Tumor Bearing Mice
Based on the MRI evaluation taken one day before RNP
injection, a group of mice bearing similarly sized tumors at
similar location was selected for systemic injection ofRNPs.
Designated amount of RNPs (1 mg/kg of mouse body
weight) prepared in 100 µL of PBS were injected through
mouse tail vein. After 15 hrs of RNP injection, the brains
were dissected out and subjected to fluorescence imaging.
Tumor volume calculated from MRI was also used to
normalize fluorescence intensity or luciferase activity for
each mouse as described below.
Fluorescence Imaging on Human Glioblastoma Xenograft
Mouse Brain Tumor
To investigate the delivery ofpRNA-3WJ RNPs in vivo,
a brain fluorescence imaging study was performed after tail
vein injection into mice bearing brain tumor. The mice were
sacrificed by cervical dislocation under anesthesia 15 hrs
post injection, and brains were dissected out of mice.
Fluorescence signals were detected from the dissected brains
using IVIS Lumina Series III Pre-clinical In Vivo Imaging
System (Perkin Elmer, Waltham, Mass.) with excitation at
640 nm and emission at 660 nm for 2 min exposure. The
fluorescence intensity was expressed as Mean Radiant Efficiency [p/s/cm2 /sr]/[µW/cm 2 ], then normalized by tumor
volume (mm 3 ). PBS injected mice were used as fluorescence
negative control. Major internal organs together with brain
from the harvested mice were collected and subjected to
fluorescence imaging for assessment of biodistribution profile study.
Bioluminescence Whole Body Imaging for Luciferase
Activity
To investigate the siRNA delivery and silencing effect of
pRNA-3WJ RNPs in vivo, U87EGFRvIII-Luc cell-induced
brain tumor was prepared into two groups of mice (n=5). At
5, 7 and 9 days post-surgery, 1 mg/kg of mouse body weight
of FA-Alexa647-pRNA-3WJ-si(Luc) RNP (or siScrm as
negative control) was injected through the mouse tail vein in
100 µL of PBS. After each injection, mice were subjected to
bioluminescence whole body imaging to detect the endogenous luciferase expression level. Mice were injected with
75 mg/kg Luciferin (Perkin Elmer, Waltham, Mass.), and
anesthetized. Bioluminescence from the anesthetized mice
was detected by ZFOV-24 zoom lens-installed IVIS Lumina
Series III Pre-clinical In Vivo Imaging System (Perkin
Elmer, Waltham, Mass.). The luminescence intensity was
expressed as Averaged Radiance [p/s/cm2 /sr], then normalized by tumor volume (mm3 ).
Statistical Analysis
All statistical analyses comparing groups of mice treated
with test and control RNPs were performed by either
ANOVA or student t-test. p<0.05 was considered significant.
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Example 2
This study is to determine the specific recognition and
binding capability ofFA-3WJ-LNA-anti-miR21 RNAnanoparticles (RNP) towards human glioblastoma cells (FIG.
9A), firstly FA-specific association between FA-3WJ-LNAmiR21 conjugated with Alexa647 fluorescent dye and
human patient-derived glioblastoma cell GBM30 was
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assessed in vitro (FIG. 9B). The nanoparticle contains a
stand of 5'-+G+A+T+A+A+G+C+T CTC CCG GCC GCC
ATG GCC GCG GGA T-3' (SEQ ID NO: 7) (underlined
sequence is 8-mer anti-miR21 LNA).
The cells plated in 6-well plate one day before RNP
binding were washed with PBS and incubated with 200 nM
ofFA-3WJ-LNA-miR21-Alexa647 RNP for 2 hrs at 37° C.
in a CO 2 incubator. After three times of washing with PBS,
the cells were harvested by trypsinization and fixed in 4%
PFA solution for 2 hrs at 4° C. and subjected to Flow
Cytometry analysis using BD FACS Aria-III Cell Sorter. The
cells were identified by staining actin filaments with Phalloidin-Alexa488. Comparison to FA-free control RNP (3WJAlexa647), flow cytometry analysis showed a higher association in FA-3WJ-LNA-miR21-Alexa647 (23.1 %) (student
t-test, p<0.001, n=3). Extra moiety of LNA-miR21 did not
affect the specific binding to the GBM30 cells, since
FA-3WJ-Alexa647 RNP showed similar level of association
(21.4%) to the FA-3WJ-LNA-miR21-Alexa647 (23.1%).

(FIG. 11). The image shows successful internalization of
FA-3WJ-LNA-miR21-Alexa647 RNP into GBM30 cells
and accumulation in cytoplasm not much in nucleus. Since
LNA-miR21 will work against mature miR-21 in cytoplasm
to show its small RNA interfering activity, the cytoplasmic
distribution of FA-3WJ-LNA-miR21-Alexa647 RNP promises the drugability in target therapy of glioblastoma.
Alexa647 was expressed in red peudocolor. The cytoskeleton of the fixed cells was stained by Alexa Fluor 488
Phalloidin (Invitrogen, Grand Island, N.Y.) and the nucleus
stained with 0.01 % DAPI solution. Fluorescence microscopy was performed using Olympus 4-filter-based FluoView
FVl000-Filter Confocal Microscope System (Olympus
Corp.) at the wavelengths of 461 nm (for the cell nucleus
stained by DAPI), 530 nm (for the cytoskeleton stained by
Alexa Fluor 488 Phalloidin) and 665 nm (for the Alexa647).
Images were analyzed by Olympus FluoView Viewer software ver. 4.0 (Olympus). The fluorescent images were
obtained using FluoView FVl000-Filter Confocal Microscope System (Olympus Corp.).
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Example 3
Example 5
In this study, the folate receptor (FR)-dependent specific
binding ofFA-3WJ-LNA-miR21-Alexa647 RNPto GBM30
cells was further confirmed by visualizing the Alexa647
signal from surface-cultured GBM30 cells treated with
FA-3WJ-LNA-miR21-Alexa647 RNP under confocal fluorescence microscope (FIG. 10). For the in vitro targeting test
ofFA-3WJ-LNA-miR21-Alexa647 RNP, 2x103 ofGBM30
cells in 200 µL were plated in Lab-Tek II 8-well chamber
slide. The next day, the cells were washed with PBS and
incubated with 200 nM of either FA-3WJ-LNA-miR21Alexa647 RNP or control RNP (3WJ-Alexa647) in 200 µL
of culture media for 2 hrs at 37° C. in a CO2 incubator. The
cytoskeleton of the fixed cells was stained by Alexa Fluor
488 Phalloidin (Invitrogen, Grand Island, N.Y.) for 30 min
at room temperature and the nucleus stained with 0.01 %
DAPI solution for 10 min at room temperature. The cells
were then rinsed with PBS for 3x10 min and mounted with
PermaFluor Aqueous Mounting Medium (Thermo Scientific). Fluorescence microscopy was performed using Olympus 4-filter-based Fluo View FVl 000-Filter Confocal Microscope System (Olympus Corp.). Higher fluorescence
intensity of Alexa647 dye was observed from GBM30 cells
treated with FA-3WJ-LNA-miR21-Alexa647 RNP than
those with control RNP (3 WJ-Alexa64 7) lacking FA. Again,
the FA-dependent association was not affected by the presence of LNA-miR21 sequences, since the FA-3WJ-LNAmiR21-Alexa647 RNP showed comparable association with
3WJ-Alexa647. When FRs of GBM30 cells were premasked by incubating with 1 mM free-folate for 1 hr of
culture before the RNP treatment, the association between
FA-3WJ-LNA-miR21-Alexa647 RNP and GBM30 cells
was abolished to an extent similar to the negative control
3WJ-Alexa647 RNP. Taken together with data shown in
FIG. 9, it indicated that the association between FA-3WJLNA-miR21-Alexa647 RNP and GBM30 cells was FR
dependent medicated by the FA conjugated to the RNP.
Yellow arrow indicates the specific localization ofFA-3WJLNA-miR21-Alexa647 RNP in GBM30 cells, which is
presented with magnified view in FIG. 11.
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Example 4
This study shows the distribution of FA-3WJ-LNAmiR21-Alexa647 RNP in GBM30 cells after 2 hrs of incubation was visualized by confocal fluorescent microscopy
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This study shows anti-tumor effect of systemically delivered FA-3WJ-LNA-miR21 RNP in human glioblastoma
cells derived tumor in vivo (FIG. 12). For in vivo test,
intracranial tumor in mice was induced by implanting GBMLuc cells expressing luciferase gene which enables the
tracing of tumor size change. Bioluminescence signal measured from the resulted brain tumor is expected to correlate
with tumor growth. To establish in vivo mouse model,
GBM30-Luc cells-induced brain tumor was prepared into
two groups of mice (n=5). At 14 days post-surgery, 1 mg/kg
of mouse body weight of FA-3WJ-LNA-miR21 RNP (or
FA-3WJ-LNA-SC as negative control) was injected through
the mouse tail vein in 100 µL of PBS for total of five times.
After each injection, mice were subjected to bioluminescence whole body imaging to detect the endogenous
luciferase expression level. Mice were injected with 75
mg/kg Luciferin (Perkin Elmer, Waltham, Mass.), and anesthetized. Bioluminescence from the anesthetized mice was
detected by ZFOV-24 zoom lens-installed IVIS Lumina
Series III Pre-clinical In Vivo Imaging System (Perkin
Elmer, Waltham, Mass.). The luminescence intensity was
expressed as Averaged Radiance [p/s/cm2 ;/sr]. When a
group of brain tumor-bearing mice (n=5) were systemically
injected with FA-3WJ-LNA-miR21 (1 mg/kg in 100 JAL of
PBS) for five times over 10 days, the luciferase activity
rapidly decreased compared to the mice group injected with
FA-3WJ-LNA-SC control RNP, indicating the anti-tumor
effect ofFA-3WJ-LNA-miR21. as the tumor grew indicating
no effect of the control RNP on luciferase gene expression.
FIG. 12A shows representative in vivo MRI images for
tumor volume and bioluminescence intensity for luciferase
activity from both FA-3WJ-LNA-miR21 or FA-3WJ-LNASC after five injections. FIG. 12B shows tumor volumes
calculated from mean fluorescence intensity compared to
scrambled control group after five injections, p=0.023 (n=5).
Example 6
This study shows the Knock-down of endogenous miR-21
in mouse tumor by systemically delivered FA-3WJ-LNAmiR21 (FIG. 13). In this study, LNA-miR21 sequences
conjugated to FA-3WJ-LNA-miR21 RNP is expected to
silence endogenous miR-21 in mouse tumor induced by
GBM30 cells. After five times of systemic administration of
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FA-3WJ-LNA-miR21 RNP, the tumor was dissected out of
mouse brain. Total RNA was extracted from the tumor tissue
with Trizol reagent according to the manufacture's protocol.
The expression level ofmiR-21 was determined by TaqMan
MicroRNA expression Reverse-transcription analysis kit.
snoRNA U6 was used as normalization internal control.
Non-tumor brains serve to show endogenous level of miR21 in normal brain cells. GBM30 cells-induced tumor
regions showed relatively higher expression of miR-21
compared to non-tumor region. When the mouse tumors
were systemically treated with FA-3WJ-LNA-miR21 RNP,
the level of miR-21 in the mouse tumors significantly
decreased at least more than two times than the mouse
tumors injected with negative control RNP, FA-3WJ-LNASC. It critically demonstrated the anti-miR-21 silencing
activity of FA-3WJ-LNA-miR21 RNP in vivo mouse models after systemic administration.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 19
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 18
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 1
uugccaugug uauguggg

<210>
<211>
<212>
<213>
<220>
<223>

18

SEQ ID NO 2
LENGTH, 20
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 2
cccacauacu uuguugaucc

20
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33
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 16
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 3
ggaucaauca uggcaa

<210>
<211>
<212>
<213>
<220>
<223>

16

SEQ ID NO 4
LENGTH, 21
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 4
cuuacgcuga guacuucgau u

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 5
LENGTH, 21
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 5
ucgaaguacu cagcguaagu u

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 6
LENGTH, 43
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 6
uugccaugug uaugugggau cccgcggcca uggcggccgg gag

<210>
<211>
<212>
<213>
<220>
<223>

43

SEQ ID NO 7
LENGTH, 33
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 7
gataagctct cccggccgcc atggccgcgg gat

<210>
<211>
<212>
<213>
<220>
<223>

33

SEQ ID NO 8
LENGTH, 22
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 8
ucuuugguua ucuagcugua ug

22
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35
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 9
LENGTH, 23
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 9
uacccuguag aaccgaauuu gug

<210>
<211>
<212>
<213>
<220>
<223>

23

SEQ ID NO 10
LENGTH, 22
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 10
uucaaguaau ccaggauagg cu

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 11
LENGTH, 22
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 11
ugagguagua gguuguauag uu

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 12
LENGTH, 21
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 12
aggcggagac uugggcaauu g

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 13
LENGTH, 22
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 13
uggcaguguc uuagcugguu gu

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 14
LENGTH, 22
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 14
cguguucaca gcggaccuug au

<210> SEQ ID NO 15

22
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37
-continued
<211>
<212>
<213>
<220>
<223>

LENGTH, 23
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 15
23

guccaguuuu cccaggaauc ccu

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 16
LENGTH, 23
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 16
23

aacauucauu gcugucggug ggu

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 17
LENGTH, 33
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 17
agcactttct cccggccgcc atggccgcgg gat

<210>
<211>
<212>
<213>
<220>
<223>

33

SEQ ID NO 18
LENGTH, 33
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 18
atttgcacct cccggccgcc atggccgcgg gat

<210>
<211>
<212>
<213>
<220>
<223>

33

SEQ ID NO 19
LENGTH, 39
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 19
39

uugccaugug uaugugggcu uacgcugagu acuucgauu

What is claimed is:
1. An artificial RNA nanostructure molecule, wherein the
molecule comprises a multiple branched RNA junction
motif comprising at least one RNA oligonucleotide, and a
brain tumor targeting module, wherein the module is
coupled to the RNA junction motif, wherein the multiple
branched RNA comprises a nucleotide sequence 5'-UUG
CCA UGU GUA UGU GGG AUC CCG CGG CCA UGG
CGG CCG GGA G-3' (SEQ ID NO: 6) or 5'-GATAAGCT
CTC CCG GCC GCC ATG GCC GCG GGA T-3' (SEQ ID
NO: 7).
2. The molecule of claim 1 further comprising at least one
bioactive agent coupled to the RNA junction motif.

55
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3. The molecule of claim 1, wherein the RNA oligonucleotide comprises at least one chemical modification at the 2'
position.
4. The molecule of claim 3, wherein the modification
comprises 2' Fluoro, 2' Amine, 2' O-Methyl, or a combination thereof.
5. The molecule of claim 1, wherein the motif is a
three-branched RNA junction motif.
6. The molecule of claim 1, wherein the diameter of the
molecule is at least about 40 nm or less.
7. The molecule of claim 1, wherein the molecule has a
zeta potential ranging from about -50 m V to about 50 m V.
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8. The molecule of claim 5, wherein a branch of the

40

19. The molecule of claim 15, wherein the bioactive agent
three-branched RNA junction motif comprises an a3WJ
is a miRNA molecule for a miRNA comprising let-7a,
RNA module (SEQ ID NO: 1); a b3WJ RNA module (SEQ
miR-l0b, miR-25, miR-34a, miR-124, miR-145, or miRID NO: 2); a c3WJ RNA module (SEQ ID NO: 3); or a
181b.
combination thereof.
20. The molecule of claim 18, wherein the anti-miRNA
9. The molecule of claim 1, wherein RNA oligonuclecomprises an anti-miRNA locked nucleic acid (LNA) molotides comprises at least 6 nucleotides in length.
ecule.
10. The molecule of claim 1, wherein the brain tumor
21. The molecule of claim 20, wherein the anti-miRNA
targeting module comprises a ligand that binds to at least one
LNA molecule comprises sequence 5'-GATAAGCT-3',
brain tumor cell surface marker.
10
5'-AGCACTTT-3', or 5'-ATTTGCAC-3'.
11. The molecule of claim 10, wherein the ligand binds to
a folate receptor, an EGFR, a transferrin receptor, an RGD,
22. The molecule of claim 15, wherein the mRNA molor a combination thereof.
ecule encodes a protein comprising VEGF, EGFR, POK,
12. The molecule of claim 10, wherein the ligand comAKT, AGT, RAF, RAS, MAPK, ERK, MGMT, MMP-2,
prises an aptamer.
MMP-9, PDGF, PDGFR, IGF-1, HGF, mTOR, Cox-2 or
15
13. The molecule of claim 11, wherein the aptamer binds
TGF~l.
to EGFR, PDGFR, folate receptor, or a combination thereof.
23. The molecule of claim 15, wherein the siRNA binds
14. The molecule of claim 1, wherein the targeting
to a mRNA molecule that encodes RAS, cMET, HER2,
module comprises a folate.
MDM2, PIK3CA, AKT, CDK4, or a combination thereof.
15. The molecule of claim 2, wherein the bioactive agent
24. A nucleic acid composition, comprising a therapeuti20
comprises a drug, a therapeutic agent, a fluorescent dye, a
cally effective amount of the RNA nano structure of claim 1.
chemical, an siRNA, an miRNA, an anti-miRNA, a
25. The composition of claim 24, further comprising a
ribozyme RNA, an antisense RNA or a combination thereof.
pharmaceutically acceptable carrier.
16. The molecule of claim 2, wherein the bioactive agent
26. The artificial RNA nanostructure of claim 1, wherein
is directed to a brain tumor marker.
17. The molecule of claim 15, wherein the microRNA 25 the RNA nanostructure comprises a nanoparticle delivery
system.
sequence is at least 6 nucleotide in length.
27. The nanoparticle delivery system of claim 26, further
18. The molecule of claim 15, wherein the bioactive agent
comprising
a pharmaceutically acceptable carrier.
is an anti-miRNAmolecule for a miRNAcomprising miR-9,
miR-l0b, miR-21, miR-17, or miR-26.
* * * * *

